MXPA02001911A - Anticuerpos ctla-4 humanos y sus usos. - Google Patents

Anticuerpos ctla-4 humanos y sus usos.

Info

Publication number
MXPA02001911A
MXPA02001911A MXPA02001911A MXPA02001911A MXPA02001911A MX PA02001911 A MXPA02001911 A MX PA02001911A MX PA02001911 A MXPA02001911 A MX PA02001911A MX PA02001911 A MXPA02001911 A MX PA02001911A MX PA02001911 A MXPA02001911 A MX PA02001911A
Authority
MX
Mexico
Prior art keywords
antibodies
human ctla
human
ctla
infections
Prior art date
Application number
MXPA02001911A
Other languages
English (en)
Spanish (es)
Inventor
Alan J Korman
Original Assignee
Medarex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medarex Inc filed Critical Medarex Inc
Publication of MXPA02001911A publication Critical patent/MXPA02001911A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0325—Animal model for autoimmune diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Environmental Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
MXPA02001911A 1999-08-24 2000-08-24 Anticuerpos ctla-4 humanos y sus usos. MXPA02001911A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15045299P 1999-08-24 1999-08-24
PCT/US2000/023356 WO2001014424A2 (en) 1999-08-24 2000-08-24 Human ctla-4 antibodies and their uses

Publications (1)

Publication Number Publication Date
MXPA02001911A true MXPA02001911A (es) 2003-07-21

Family

ID=22534598

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02001911A MXPA02001911A (es) 1999-08-24 2000-08-24 Anticuerpos ctla-4 humanos y sus usos.

Country Status (21)

Country Link
US (1) US6984720B1 (enExample)
EP (4) EP3214175A1 (enExample)
JP (4) JP4093757B2 (enExample)
KR (3) KR20020047132A (enExample)
CN (2) CN102766210B (enExample)
AT (1) ATE354655T1 (enExample)
AU (3) AU784012B2 (enExample)
BE (1) BE2012C001I2 (enExample)
CA (2) CA2589418A1 (enExample)
CY (2) CY1107628T1 (enExample)
DE (2) DE60033530T2 (enExample)
DK (1) DK1212422T3 (enExample)
ES (1) ES2282133T3 (enExample)
FR (1) FR12C0004I2 (enExample)
IL (3) IL148079A0 (enExample)
LU (1) LU91928I2 (enExample)
MX (1) MXPA02001911A (enExample)
NZ (1) NZ517202A (enExample)
PT (1) PT1212422E (enExample)
WO (1) WO2001014424A2 (enExample)
ZA (1) ZA200201190B (enExample)

Families Citing this family (1117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
ATE397457T1 (de) * 1998-12-03 2008-06-15 Univ California Stimulierung von t-zellen gegen selbstantigene unter verwendung von ctla-4 inhibierenden wirkstoffen
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
ES2706547T3 (es) * 1998-12-23 2019-03-29 Pfizer Anticuerpos monoclonales humanos para CTLA-4
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
NZ517202A (en) * 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
AU2001233027A1 (en) * 2000-01-27 2001-08-07 Genetics Institute, Llc Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof
GB2361704C (en) 2000-03-03 2006-08-02 Cambridge Antibody Tech Human antibodies against eotaxin and their use
US6946546B2 (en) 2000-03-06 2005-09-20 Cambridge Antibody Technology Limited Human antibodies against eotaxin
PT2990420T (pt) 2000-05-26 2017-03-16 Immunex Corp Uso de anticorpos de recetor de interleucina-4 e composições dos mesmos
AU2002231736A1 (en) 2000-12-22 2002-07-08 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Use of repulsive guidance molecule (rgm) and its modulators
WO2002079447A2 (en) 2001-03-30 2002-10-10 Avigenics, Inc. Avian lysozyme promoter
US7541512B2 (en) 2001-03-30 2009-06-02 Synageva Biopharma Corp. Avians containing a lysozyme promoter transgene
IL149701A0 (en) * 2001-05-23 2002-11-10 Pfizer Prod Inc Use of anti-ctla-4 antibodies
AR038568A1 (es) * 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
NZ536420A (en) 2002-04-12 2008-04-30 Medarex Inc Methods of treatment using CTLA-4 antibodies
CN1665533A (zh) * 2002-05-02 2005-09-07 康涅狄格大学健康中心 热激蛋白用于增强抗体疗法功效的用途
PT2298278E (pt) 2002-06-07 2016-02-25 Dyax Corp Prevenção e redução da perda de sangue e resposta inflamatória
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
DE60334303D1 (de) 2002-07-03 2010-11-04 Tasuku Honjo Immunpotenzierende zusammensetzungen
WO2004019968A1 (en) 2002-08-28 2004-03-11 Dyax Corp. Methods for preserving organs and tissues
EP1581648A2 (en) * 2002-09-09 2005-10-05 Nura, Inc. G protein coupled receptors and uses thereof
US20080260744A1 (en) * 2002-09-09 2008-10-23 Omeros Corporation G protein coupled receptors and uses thereof
WO2004029629A1 (en) * 2002-09-27 2004-04-08 Janssen Pharmaceutica N.V. N-11 truncated amyloid-beta nomoclonal antibodies, compositions, methods and uses
JP2006500931A (ja) * 2002-09-30 2006-01-12 ファイザー・プロダクツ・インク 高レベルのヒト配列抗体を産生するハイブリドーマ
KR100944575B1 (ko) * 2002-10-17 2010-02-25 젠맵 에이/에스 Ｃｄ20에 대한 인간 모노클로날 항체
NZ541050A (en) 2002-12-16 2010-06-25 Genmab As Human monoclonal antibodies against interleukin 8 (IL-8)
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
MXPA05009556A (es) 2003-03-14 2005-11-16 Wyeth Corp Anticuerpos contra receptor de il-21 humano y sus usos.
CA2519113C (en) 2003-04-02 2012-06-05 F. Hoffmann-La Roche Ag Antibodies against insulin-like growth factor i receptor and uses thereof
CA2522957C (en) 2003-04-23 2013-10-22 Medarex, Inc. Compositions and methods for the therapy of inflammatory bowel disease
US7465446B2 (en) 2003-05-30 2008-12-16 Medarex, Inc. Surrogate therapeutic endpoint for anti-CTLA4-based immunotherapy of disease
WO2005048917A2 (en) * 2003-06-06 2005-06-02 Medimmune, Inc. Use of epha4 and modulator or epha4 for diagnosis, treatment and prevention of cancer
AR046071A1 (es) 2003-07-10 2005-11-23 Hoffmann La Roche Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
US8101720B2 (en) * 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
EP1531162A1 (en) * 2003-11-14 2005-05-18 Heinz Vollmers Adenocarcinoma specific antibody SAM-6, and uses thereof
US7642341B2 (en) 2003-12-18 2010-01-05 Merck Serono S.A. Angiogenesis inhibiting molecules, their selection, production and their use in the treatment of cancer
EP1533617A1 (en) 2003-11-19 2005-05-25 RMF Dictagene S.A. Angiogenesis inhibiting molecules, their selection, production and their use in the treatment and diagnosis of cancer
DK2383295T3 (en) 2003-12-10 2015-06-15 Squibb & Sons Llc Ip-10 antibodies and uses thereof
PT2418220T (pt) 2003-12-10 2017-10-04 Squibb & Sons Llc Anticorpos contra interferão alfa e suas utilizações
ES2366626T3 (es) 2004-02-06 2011-10-24 University Of Massachusetts Anticuerpos contra toxinas de clostridium difficile y usos de los mismos.
KR100845354B1 (ko) * 2004-03-26 2008-07-09 화이자 프로덕츠 인코포레이티드 항－ｃｔｌａ－4 항체의 용도
WO2005100402A1 (en) 2004-04-13 2005-10-27 F.Hoffmann-La Roche Ag Anti-p-selectin antibodies
US7378504B2 (en) 2004-06-03 2008-05-27 Medarex, Inc. Human monoclonal antibodies to Fc gamma receptor I (CD64)
US7494779B2 (en) 2004-06-14 2009-02-24 Li-Te Chin Method for producing human antibodies to human CD152 with properties of agonist, antagonist, or inverse agonist
EP1773406A4 (en) * 2004-06-15 2008-09-03 Centocor Inc METHOD FOR SCREENING AGENTS AGAINST DISEASE OF HUMAN PROSTATE
ES2643237T3 (es) 2004-06-21 2017-11-21 E. R. Squibb & Sons, L.L.C. Anticuerpos del receptor 1 de interferón alfa y sus usos
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
US7892827B2 (en) 2004-11-26 2011-02-22 Pieris Ag Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
AU2005313020A1 (en) * 2004-12-09 2006-06-15 Neuro Therapeutics Ab Materials and methods related to Dickkopfs (DKK) and Neurogenesis
EP1860120B1 (en) * 2005-02-08 2018-01-24 The Chemo-Sero-Therapeutic Research Institute Method for improving antibody
AU2012200203B2 (en) * 2005-03-08 2014-07-03 Pfizer Products Inc. Anti-CTLA-4 Antibody Compositions
EP1865986B1 (en) * 2005-03-08 2016-02-17 Pfizer Products Inc. Anti-ctla-4 antibody compositions
AU2014240252B2 (en) * 2005-03-08 2016-10-06 Pfizer Products Inc Anti-CTLA-4 Antibody Compositions
EP2551282A3 (en) 2005-03-23 2013-02-13 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
MX2007010603A (es) * 2005-03-23 2007-10-18 Pfizer Prod Inc Terapia de cancer de prostata con anticuerpos contra ctla4 y terapia hormonal.
US20060240006A1 (en) * 2005-04-20 2006-10-26 Chishih Chu Novel antibody structures derived from human germline sequences
DE102005019845A1 (de) * 2005-04-28 2006-11-02 Li-Te Chin Neue aus humanen Keimbahnsequenzen gewonnene Antikörperstrukturen
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
DK1907000T4 (da) 2005-06-08 2020-03-30 The President And Fellows Of Harvard College Fremgangsmåder og sammensætninger til behandling af persisterende HIV-infektioner ved hæmning af reaktionsvejen for programmeret celledød 1 (PD-1).
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
WO2007008463A2 (en) * 2005-07-07 2007-01-18 Coley Pharmaceutical Group, Inc. Anti-ctla-4 antibody and cpg-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment
DK1915398T3 (en) * 2005-07-18 2016-07-04 Amgen Inc Humane anti-B7RP1 neutraliserende antistoffer
CN100443503C (zh) * 2005-07-18 2008-12-17 四川大学华西医院 人源化ctla-4单链抗体与人穿孔素通道形成肽p34的重组免疫毒素
NL1029605C2 (nl) * 2005-07-25 2007-01-26 Li-Te Chin Nieuwe uit menselijke kiemlijnsequenties gewonnen antilichaamstructuren.
DK2594591T3 (en) * 2005-08-11 2018-07-30 Matossian Rogers Arpi TCR-V-BETA RELATED PEPTIDES FOR TREATMENT AND DIAGNOSIS OF AUTOIMMUNE DISEASE
EP1934261B1 (en) 2005-09-26 2014-10-29 Medarex, L.L.C. Human monoclonal antibodies to cd70
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
CN101277974A (zh) * 2005-09-30 2008-10-01 阿伯特有限及两合公司 排斥性引导分子(rgm)蛋白质家族的蛋白质的结合结构域及其功能性片段和它们的用途
EP2532677A1 (en) 2005-10-21 2012-12-12 Novartis AG Human antibodies against il13 and therapeutic uses
US7611702B2 (en) 2005-11-08 2009-11-03 Medarex, Inc. TNF-alpha blocker treatment for enterocolitis associated with immunostimulatory therapeutic antibody therapy
RU2442793C2 (ru) 2005-11-30 2012-02-20 Эбботт Лэборетриз АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ
PL1976877T5 (pl) 2005-11-30 2017-09-29 Abbvie Inc Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania
NZ568016A (en) * 2005-12-07 2011-12-22 Medarex Inc CTLA-4 antibody dosage escalation regimens
EA017491B1 (ru) 2005-12-08 2012-12-28 Медарекс, Инк. Человеческие моноклональные антитела к фукозил-gm1 и способы применения антифукозил-gm1 антител
US20090175886A1 (en) 2006-01-17 2009-07-09 Medarex, Inc. Monoclonal antibodies against cd30 lacking in fucosyl and xylosyl residues
WO2007123737A2 (en) 2006-03-30 2007-11-01 University Of California Methods and compositions for localized secretion of anti-ctla-4 antibodies
US7919079B2 (en) * 2006-03-31 2011-04-05 Biosante Pharmaceuticals, Inc. Cancer immunotherapy compositions and methods of use
JP5514539B2 (ja) 2006-03-31 2014-06-04 メダレックス・リミテッド・ライアビリティ・カンパニー ヒト抗体の調製に用いるためのキメラ抗体を発現するトランスジェニック動物
US8524454B2 (en) * 2006-04-07 2013-09-03 The Research Foundation Of State University Of New York Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
AU2007234733A1 (en) 2006-04-07 2007-10-18 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Antibody compositions and methods for treatment of neoplastic disease
US9044461B2 (en) 2006-04-07 2015-06-02 The Research Foundation Of State University Of New York Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
JP5244785B2 (ja) 2006-08-11 2013-07-24 小野薬品工業株式会社 ストローマ由来因子−１（ｓｄｆ−１）に対するモノクローナル抗体
CN101627055A (zh) 2006-09-05 2010-01-13 梅达雷克斯公司 骨形成蛋白及其受体的抗体以及它们的使用方法
PL2081595T3 (pl) 2006-09-26 2019-11-29 Genmab As Anty-cd38 wraz z kortykosteroidami wraz ze środkiem chemioterapeutycznym niebędącym kortykosteroidem, do leczenia guzów nowotworowych
AU2007301599B2 (en) 2006-09-28 2013-01-10 Merck Serono S.A. Junctional Adhesion Molecule-C (JAM-C) binding compounds and methods of their use
SI2066351T1 (sl) 2006-10-02 2016-02-29 E.R. Squibb & Sons, L.L.C. Humana protitelesa, ki vežejo cxcr4 in njihova uporaba
PL2068922T3 (pl) 2006-10-19 2012-11-30 Csl Ltd Przeciwciała anty-IL-13R alfa1 i ich zastosowania
US8618248B2 (en) 2006-10-31 2013-12-31 President And Fellows Of Harvard College Phosphopeptide compositions and anti-phosphopeptide antibody compositions and methods of detecting phosphorylated peptides
MX2009005189A (es) 2006-11-15 2009-06-30 Medarex Inc Anticuerpos humanos monoclonales para btla y metodos de uso.
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
SG177168A1 (en) 2006-12-01 2012-01-30 Medarex Inc Human antibodies that bind cd22 and uses thereof
CL2007003622A1 (es) 2006-12-13 2009-08-07 Medarex Inc Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
US20100150950A1 (en) 2006-12-14 2010-06-17 Medarex, Inc. Human antibodies that bind cd70 and uses thereof
WO2009077483A1 (en) 2007-12-14 2009-06-25 Novo Nordisk A/S Antibodies against human nkg2d and uses thereof
NZ579644A (en) 2007-02-16 2012-05-25 Merrimack Pharmaceuticals Inc Antibodies against erbb3 and uses thereof
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US20100099090A1 (en) * 2007-03-05 2010-04-22 Bristol-Mayers Squibb Company Biomarkers and methods for determining sensitivity to ctla-4 antagonists
EP2626372B1 (en) 2007-03-29 2018-03-21 Genmab A/S Bispecific antibodies and methods for production thereof
FI20075278A0 (fi) 2007-04-20 2007-04-20 Biotie Therapies Corp Uudet täysin ihmisperäiset anti-VAP-1 monoklonaaliset vasta-aineet
AU2008255352B2 (en) 2007-05-31 2014-05-22 Genmab A/S Stable IgG4 antibodies
JP5588866B2 (ja) 2007-08-10 2014-09-10 メダレックス エル．エル．シー． Ｈｃｏ３２およびｈｃｏ２７、ならびに関連実施例
EP2185188B1 (en) 2007-08-22 2014-08-06 Medarex, L.L.C. Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions
EP2190861A4 (en) 2007-08-22 2011-03-30 Univ California ACTIVE BINDING POLYPEPTIDES AND METHOD FOR THEIR IDENTIFICATION AND USE
SI2769729T1 (sl) 2007-09-04 2019-06-28 Compugen Ltd. Polipeptidin in polinukleotidi in njihove uporabe kot tarča zdravila za izdelavo zdravil in bioloških zdravil
EP2033971A1 (de) * 2007-09-06 2009-03-11 Abbott GmbH & Co. KG Bone Morphogenetic Protein (BMP)-bindende Domänen von Proteinen der Repulsive Guidance Molecule (RGM) Proteinfamilie und funktionale Fragmente davon sowie deren Verwendung
AR068767A1 (es) 2007-10-12 2009-12-02 Novartis Ag Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
MX2010004761A (es) 2007-11-02 2010-05-19 Novartis Ag Moleculas y metodos para modular la proteina relacionada con el receptor de lipoproteina de baja densidad 6 (lrp6).
US8449886B2 (en) 2008-01-08 2013-05-28 Bristol-Myers Squibb Company Combination of anti-CTLA4 antibody with tubulin modulating agents for the treatment of proliferative diseases
WO2009100140A1 (en) * 2008-02-04 2009-08-13 Medarex, Inc. Anti-clta-4 antibodies with reduced blocking of binding of ctla-4 to b7 and uses thereof
WO2009100110A1 (en) 2008-02-05 2009-08-13 Medarex, Inc. Alpha 5 - beta 1 antibodies and their uses
US8962803B2 (en) * 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
AU2009255357A1 (en) * 2008-05-29 2009-12-10 Bristol-Myers Squibb Company Methods for predicting patient response to modulation of the co-stimulatory pathway
WO2010014784A2 (en) 2008-08-01 2010-02-04 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
PY09026846A (es) 2008-08-05 2015-09-01 Novartis Ag Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
WO2010042433A1 (en) 2008-10-06 2010-04-15 Bristol-Myers Squibb Company Combination of cd137 antibody and ctla-4 antibody for the treatment of proliferative diseases
MX2011005691A (es) * 2008-11-28 2011-07-20 Univ Emory Metodos para el tratamiento de infecciones y tumores.
CA2745439C (en) 2008-12-03 2019-10-15 Genmab A/S Antibody variants having modifications in the constant region
WO2010067308A2 (en) 2008-12-08 2010-06-17 Compugen Ltd. Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
UA109633C2 (uk) 2008-12-09 2015-09-25 Антитіло людини проти тканинного фактора
JP2013516389A (ja) 2009-01-06 2013-05-13 ダイアックス コーポレーション カリクレイン阻害剤による粘膜炎治療
EP3543256A1 (en) 2009-01-12 2019-09-25 Cytomx Therapeutics Inc. Modified antibody compositions, methods of making and using thereof
ES2568509T3 (es) * 2009-01-15 2016-04-29 Adaptive Biotechnologies Corporation Perfilado de la inmunidad adaptativa y métodos para la generación de anticuerpos monoclonales
US8399219B2 (en) 2009-02-23 2013-03-19 Cytomx Therapeutics, Inc. Protease activatable interferon alpha proprotein
GB0903325D0 (en) 2009-02-26 2009-04-08 Univ Aberdeen Antibody molecules
JP5816558B2 (ja) 2009-03-05 2015-11-18 メダレックス・リミテッド・ライアビリティ・カンパニーＭｅｄａｒｅｘ， Ｌ．Ｌ．Ｃ． Ｃａｄｍ１に特異的な完全ヒト抗体
ES2581488T3 (es) 2009-04-08 2016-09-06 Lipum Ab Nuevos métodos para el tratamiento de enfermedades inflamatorias
WO2010124113A1 (en) 2009-04-23 2010-10-28 Infinity Pharmaceuticals, Inc. Anti-fatty acid amide hydrolase-2 antibodies and uses thereof
CA2759942A1 (en) 2009-04-27 2010-10-07 Novartis Ag Composition and methods of use for therapeutic antibodies specific for the il-12 receptore betai subunit
ES2655877T3 (es) 2009-04-27 2018-02-22 Novartis Ag Composiciones y métodos para aumentar el crecimiento muscular
EP2445925A1 (en) 2009-06-25 2012-05-02 Bristol-Myers Squibb Company Protein purification by caprylic acid (octanoic acid) precipitation
PT2769737T (pt) 2009-07-20 2017-06-29 Bristol Myers Squibb Co Combinação de um anticorpo anti-ctla4 com etopósido para o tratamento sinérgico de doenças proliferativas
US8394922B2 (en) 2009-08-03 2013-03-12 Medarex, Inc. Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof
WO2011021146A1 (en) 2009-08-20 2011-02-24 Pfizer Inc. Osteopontin antibodies
US20120178910A1 (en) 2009-09-23 2012-07-12 Medarex, Inc. Cation exchange chromatography (methods)
WO2011041613A2 (en) * 2009-09-30 2011-04-07 Memorial Sloan-Kettering Cancer Center Combination immunotherapy for the treatment of cancer
US8435516B2 (en) 2009-10-12 2013-05-07 Pfizer Inc. Cancer treatment
US20110117087A1 (en) 2009-10-26 2011-05-19 Reinhard Franze Method for the production of a glycosylated immunoglobulin
DK2501822T3 (da) 2009-11-17 2017-11-27 Squibb & Sons Llc Fremgangsmåder til forbedret proteinproduktion
WO2011067711A2 (en) 2009-12-01 2011-06-09 Compugen Ltd Novel heparanase splice variant
PH12012501070A1 (en) 2009-12-08 2017-08-23 Abbott Gmbh & Co Kg Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration
ES2905545T3 (es) 2010-01-06 2022-04-11 Takeda Pharmaceuticals Co Proteínas de unión a calicreína plasmática
EP3904391B1 (en) 2010-03-10 2024-07-10 Genmab A/S Monoclonal antibodies against c-met
EP2550359B1 (en) 2010-03-23 2017-08-09 Intrexon Corporation Vectors conditionally expressing therapeutic proteins, host cells comprising the vectors, and uses thereof
CN103119054B (zh) 2010-03-26 2017-01-18 达特茅斯大学理事会 Vista调节性t细胞介体蛋白、vista结合剂及其用途
US20150231215A1 (en) 2012-06-22 2015-08-20 Randolph J. Noelle VISTA Antagonist and Methods of Use
US10745467B2 (en) 2010-03-26 2020-08-18 The Trustees Of Dartmouth College VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
WO2011130377A2 (en) 2010-04-15 2011-10-20 Abbott Laboratories Amyloid-beta binding proteins
WO2011140151A1 (en) 2010-05-04 2011-11-10 Dyax Corp. Antibodies against epidermal growth factor receptor (egfr)
WO2011140254A1 (en) 2010-05-04 2011-11-10 Adimab, Llc Antibodies against epidermal growth factor receptor (egfr) and uses thereof
SG185416A1 (en) 2010-05-06 2012-12-28 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
MX2012012927A (es) 2010-05-06 2013-05-01 Novartis Ag Composiciones y metodos de uso para anticuerpos multivalentes terapeuticos de proteina relacionada con lipoproteina de baja densidad 6 (lrp6).
US20130064831A1 (en) 2010-05-17 2013-03-14 Bristol-Myers Squibb Company Immunotherapeutic dosing regimens and combinations thereof
NZ604007A (en) 2010-05-27 2015-03-27 Genmab As Monoclonal antibodies against her2 epitope
IL299365A (en) 2010-05-27 2023-02-01 Genmab As Monoclonal antibodies against 2HER
EP2580243B1 (en) 2010-06-09 2019-10-16 Genmab A/S Antibodies against human cd38
JP6055404B2 (ja) 2010-06-15 2016-12-27 ゲンマブ エー／エス 組織因子に対するヒト抗体薬物結合体
CA2803391C (en) 2010-06-22 2021-11-09 Neogenix Oncology, Inc. Npc1 antibodies that bind a muc5ac epitope
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
ME02637B (me) 2010-08-20 2017-06-20 Novartis Ag Antitela za receptor 3 faktora rasta epiderma (her3)
EP2616100B1 (en) 2010-09-17 2016-08-31 Compugen Ltd. Compositions and methods for treatment of drug resistant multiple myeloma
EP2622091B1 (en) 2010-09-23 2019-03-13 Precision Biologics, Inc. Colon and pancreas cancer peptidomimetics
EP2857499A1 (en) 2010-10-01 2015-04-08 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2625203A1 (en) 2010-10-05 2013-08-14 Novartis AG Anti-il12rbeta1 antibodies and their use in treating autoimmune and inflammatory disorders
WO2012069466A1 (en) 2010-11-24 2012-05-31 Novartis Ag Multispecific molecules
US9221885B2 (en) 2010-12-02 2015-12-29 Pieris Ag Muteins of human lipocalin 2 with affinity for CTLA-4
PL2651975T3 (pl) 2010-12-14 2018-04-30 Dso Nat Laboratories Ludzkie przeciwciało monoklonalne o swoistości względem białka e wirusa denga serotypu 1 i jego zastosowania
WO2012088446A1 (en) 2010-12-22 2012-06-28 Board Of Trustees Of The Leland Stanford Junior University Superagonists and antagonists of interleukin-2
KR102011156B1 (ko) 2011-01-06 2019-08-16 다이액스 코포레이션 혈장 칼리크레인 결합 단백질
WO2012118693A1 (en) 2011-02-28 2012-09-07 Northshore University Healthsystem Methods of diagnosing clostridium difficile infection
GB201103955D0 (en) * 2011-03-09 2011-04-20 Antitope Ltd Antibodies
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
WO2012136552A1 (en) 2011-04-08 2012-10-11 H. Lundbeck A/S ANTIBODIES SPECIFIC TO PYROGLUTAMATED Αβ
WO2012142164A1 (en) 2011-04-12 2012-10-18 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Human monoclonal antibodies that bind insulin-like growth factor (igf) i and ii
RU2623161C2 (ru) 2011-04-15 2017-06-22 Компуджен Лтд. Полипептиды и полинуклеотиды и их применение для лечения иммунологических нарушений и рака
CA2832387A1 (en) 2011-04-20 2012-10-26 Genmab A/S Bispecifc antibodies against her2
WO2012143524A2 (en) 2011-04-20 2012-10-26 Genmab A/S Bispecific antibodies against her2 and cd3
EP2699260B1 (en) 2011-04-20 2024-11-20 Genmab A/S Bispecifc antibodies against her2
WO2012149540A1 (en) 2011-04-28 2012-11-01 The Broad Institute Inc Inhibitors of histone deacetylase
US9067997B2 (en) 2011-05-25 2015-06-30 Innate Pharma Sa Anti-KIR antibodies for the treatment of inflammatory and autoimmune disorders
US8852599B2 (en) 2011-05-26 2014-10-07 Bristol-Myers Squibb Company Immunoconjugates, compositions for making them, and methods of making and use
US8691231B2 (en) 2011-06-03 2014-04-08 Merrimack Pharmaceuticals, Inc. Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
WO2012172495A1 (en) 2011-06-14 2012-12-20 Novartis Ag Compositions and methods for antibodies targeting tem8
EP2726503B1 (en) 2011-06-30 2019-09-04 Compugen Ltd. Polypeptides and uses thereof for treatment of autoimmune disorders and infection
WO2013002362A1 (ja) 2011-06-30 2013-01-03 中外製薬株式会社 ヘテロ二量化ポリペプチド
JP6472999B2 (ja) 2011-07-01 2019-02-20 ノバルティス アーゲー 代謝障害を治療するための方法
UA117901C2 (uk) 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
US9238689B2 (en) 2011-07-15 2016-01-19 Morpho Sys AG Antibodies that are cross-reactive for macrophage migration inhibitory factor (MIF) and D-dopachrome tautomerase (D-DT)
US9120858B2 (en) 2011-07-22 2015-09-01 The Research Foundation Of State University Of New York Antibodies to the B12-transcobalamin receptor
HUE042327T2 (hu) 2011-08-30 2019-06-28 Astex Pharmaceuticals Inc Decitabin-származék készítmények
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
PT3682905T (pt) 2011-10-03 2022-04-07 Modernatx Inc Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações
RS53496B1 (sr) * 2011-10-04 2015-02-27 Affiris Ag POSTUPAK ZA DETEKCIJU Aβ-SPECIFIČNIH ANTITELA U BIOLOŠKOM UZORKU
ES2769786T3 (es) 2011-10-14 2020-06-29 Recordati Ag Anticuerpos y métodos para enfermedades relacionadas con la vía Wnt
CN108341873B (zh) 2011-12-05 2022-03-25 诺华股份有限公司 表皮生长因子受体3(her3)的抗体
EP2788382A2 (en) 2011-12-05 2014-10-15 Novartis AG Antibodies for epidermal growth factor receptor 3 (her3) directed to domain ii of her3
MX357708B (es) 2011-12-14 2018-07-20 Abbvie Deutschland Composicion y metodo para el diagnostico y tratamiento de trastornos relacionados con hierro.
CN104136462B (zh) 2011-12-14 2017-06-09 艾伯维德国有限责任两合公司 用于诊断和治疗铁相关病症的组合物和方法
ES2923757T3 (es) 2011-12-16 2022-09-30 Modernatx Inc Composiciones de ARNm modificado
SG10201703249PA (en) 2011-12-21 2017-05-30 Novartis Ag Compositions and methods for antibodies targeting factor p
AU2013211939C1 (en) 2012-01-27 2018-06-07 AbbVie Deutschland GmbH & Co. KG Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
AU2013216320A1 (en) 2012-02-01 2014-04-03 Compugen Ltd. C10RF32 antibodies, and uses thereof for treatment of cancer
PL2814829T3 (pl) 2012-02-13 2017-06-30 Bristol-Myers Squibb Company Związki enediyny, ich koniugaty oraz zastosowanie i sposoby ich wytwarzania
US10077478B2 (en) 2012-03-05 2018-09-18 Adaptive Biotechnologies Corp. Determining paired immune receptor chains from frequency matched subunits
WO2013151664A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
WO2013138702A2 (en) 2012-03-15 2013-09-19 Bristol-Myers Squibb Company Methods for predicting gastrointestinal immune-related adverse events (gi-irae) in patients treated with modulation of the co-stimulatory pathway
US20150079100A1 (en) 2012-03-23 2015-03-19 Bristol-Myers Squibb Company Methods of treatments using ctla-4 antibodies
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
PL2844282T3 (pl) 2012-05-04 2019-11-29 Pfizer Antygeny związane z gruczołem krokowym i schematy immunoterapii oparte na szczepionce
PT2831276T (pt) 2012-05-08 2016-07-26 Adaptive Biotechnologies Corp Composições e método para medição e calibração do viés de amplificação em reações pcr multiplex
WO2013169971A1 (en) 2012-05-10 2013-11-14 Bristol-Myers Squibb Company Anti-tumor antibodies as predictive or prognostic biomarkers of efficacy and survival in ipilimumab-treated patients
US9856320B2 (en) 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
CN104619722B (zh) 2012-06-22 2022-10-04 达特茅斯大学理事会 新型vista-ig构建体和vista-ig用于治疗自身免疫性、过敏性和炎性疾病的用途
US9890215B2 (en) 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
EP3632462A1 (en) 2012-07-06 2020-04-08 Genmab B.V. Dimeric protein with triple mutations
WO2014006217A1 (en) 2012-07-06 2014-01-09 Genmab B.V. Dimeric protein with triple mutations
EP2877444B1 (en) 2012-07-27 2020-09-02 The Broad Institute, Inc. Inhibitors of histone deacetylase
US9382329B2 (en) 2012-08-14 2016-07-05 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to Trop-2 expressing cells
EA201590451A1 (ru) 2012-08-30 2016-05-31 Эмджен Инк. Способ лечения меланомы с применением вируса простого герпеса и ингибитора иммунной контрольной точки
CA2884704C (en) 2012-09-07 2023-04-04 Randolph J. Noelle Vista modulators for diagnosis and treatment of cancer
US9376489B2 (en) 2012-09-07 2016-06-28 Novartis Ag IL-18 binding molecules
WO2015160439A2 (en) 2014-04-17 2015-10-22 Adaptive Biotechnologies Corporation Quantification of adaptive immune cell genomes in a complex mixture of cells
CA2889182A1 (en) 2012-10-26 2014-05-01 The University Of Chicago Synergistic combination of immunologic inhibitors for the treatment of cancer
KR102149206B1 (ko) 2012-11-08 2020-08-31 세센 바이오, 아이엔씨. 인터루킨-6의 길항제 및 이의 용도
PT2922554T (pt) 2012-11-26 2022-06-28 Modernatx Inc Arn modificado nas porções terminais
WO2014084859A1 (en) 2012-11-30 2014-06-05 Novartis Ag Molecules and methods for modulating tmem16a activities
SMT201900242T1 (it) 2012-12-03 2019-05-10 Bristol Myers Squibb Co Incremento dell'attivita' anti-cancro di proteine di fuzione a fc immunomodulatrici
DK2928921T3 (da) 2012-12-05 2021-04-19 Novartis Ag Sammensætninger og fremgangsmåder til antistoffer målrettet epo
KR20150095684A (ko) 2012-12-18 2015-08-21 노파르티스 아게 히알루로난에 결합하는 펩티드 태그를 이용하는 조성물 및 방법
EP3336104A1 (en) 2012-12-28 2018-06-20 Precision Biologics, Inc. Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer
MX387324B (es) 2013-01-10 2025-03-18 Genmab Bv Variantes de regiones fc de igg1 de humano y usos de las mismas.
LT2953969T (lt) 2013-02-08 2019-12-10 Novartis Ag Anti-il-17a antikūnai ir jų panaudojimas autoimuninių ir uždegiminių ligų gydymui
DK2956173T3 (en) 2013-02-14 2017-07-17 Bristol Myers Squibb Co TUBULYSIS RELATIONSHIPS, METHODS OF PRODUCING AND USING THEREOF
CN105025884B (zh) 2013-03-01 2019-08-20 阿斯泰克斯制药公司 药物组合
PH12022550138A1 (en) 2013-03-13 2023-03-06 Amgen Inc Proteins specific for baff and b7rp1 and uses thereof
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
WO2014153150A1 (en) * 2013-03-14 2014-09-25 Lee Delphine J Methods of predicting anti ctla-4 response and recurrence of cancer
WO2014159239A2 (en) 2013-03-14 2014-10-02 Novartis Ag Antibodies against notch 3
US9469686B2 (en) 2013-03-15 2016-10-18 Abbott Laboratories Anti-GP73 monoclonal antibodies and methods of obtaining the same
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US20160030384A1 (en) 2013-04-09 2016-02-04 Boston Biomedical, Inc. 2-acetylnaphtho[2,3-b]furan -4,9-dione for use on treating cancer
KR101472903B1 (ko) 2013-05-16 2014-12-16 (주)케어젠 T 세포 활성 억제 펩타이드 및 이의 용도
CA2922704A1 (en) 2013-05-24 2014-11-27 Neil R. Cashman Cell senescence markers as diagnostic and therapeutic targets
EP3003372B1 (en) 2013-06-07 2019-10-09 Duke University Inhibitors of complement factor h
AR096601A1 (es) 2013-06-21 2016-01-20 Novartis Ag Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
US9708657B2 (en) 2013-07-01 2017-07-18 Adaptive Biotechnologies Corp. Method for generating clonotype profiles using sequence tags
SI3030575T1 (sl) 2013-08-08 2018-11-30 Cytune Pharma Modulokini na osnovi IL-15 in IL-15R-alfa sushi domene
CA2920539C (en) 2013-08-08 2024-01-02 Cytune Pharma Combined pharmaceutical composition
JP6474404B2 (ja) 2013-08-14 2019-02-27 ウィリアム マーシュ ライス ユニバーシティＷｉｌｌｉａｍ Ｍａｒｓｈ Ｒｉｃｅ Ｕｎｉｖｅｒｓｉｔｙ ウンシアラマイシン誘導体、合成方法、および抗腫瘍薬としてのそれらの使用
WO2015022658A2 (en) 2013-08-14 2015-02-19 Novartis Ag Methods of treating sporadic inclusion body myositis
RS64268B1 (sr) 2013-09-20 2023-07-31 Bristol Myers Squibb Co Kombinacija anti-lag-3 antitela i anti-pd-1 antitela za lečenje tumora
CN105722860A (zh) 2013-09-24 2016-06-29 梅迪塞纳医疗股份有限公司 白介素-2融合蛋白及其应用
EP3049442A4 (en) 2013-09-26 2017-06-28 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
MX377714B (es) 2013-10-18 2025-03-11 Regeneron Pharma Composiciones que comprenden una combinación de un antagonista de vegf y un anticuerpo anti-ctla-a.
EP3524262A1 (en) 2013-11-01 2019-08-14 Pfizer Inc Vectors for expression of prostate-associated antigens
EA201690912A1 (ru) 2013-11-05 2016-10-31 Когнейт Биосервисис, Инк. Комбинации ингибиторов контрольных точек и терапевтических средств для лечения рака
EP3066127A1 (en) 2013-11-06 2016-09-14 Bristol-Myers Squibb Company Immunotherapeutic dosing regimens and combinations thereof
US11014987B2 (en) 2013-12-24 2021-05-25 Janssen Pharmaceutics Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
US10273301B2 (en) 2013-12-24 2019-04-30 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments
AU2015205530B8 (en) 2014-01-13 2019-09-19 Pieris Pharmaceuticals Gmbh Multi-specific polypeptide useful for localized tumor immunomodulation
UA122479C2 (uk) 2014-01-24 2020-11-25 Дана-Фарбер Кенсер Інстітьют, Інк. Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1)
PL3099717T3 (pl) 2014-01-31 2019-10-31 Novartis Ag Cząsteczki przeciwciała dla TIM-3 i ich zastosowanie
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
EP3114144A1 (en) 2014-03-05 2017-01-11 Bristol-Myers Squibb Company Treatment of renal cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
EA201691765A1 (ru) 2014-03-14 2016-12-30 Новартис Аг Молекулы антител против lag-3 и их применения
US11390921B2 (en) 2014-04-01 2022-07-19 Adaptive Biotechnologies Corporation Determining WT-1 specific T cells and WT-1 specific T cell receptors (TCRs)
CN104974253A (zh) * 2014-04-01 2015-10-14 上海中信国健药业股份有限公司 抗ctla-4/pd-1双特异性抗体、其制备方法及应用
US10066265B2 (en) 2014-04-01 2018-09-04 Adaptive Biotechnologies Corp. Determining antigen-specific t-cells
EP4011910A1 (en) 2014-04-03 2022-06-15 IGM Biosciences, Inc. Modified j-chain
JP6592505B2 (ja) 2014-04-24 2019-10-16 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー インターロイキン−２のスーパーアンタゴニスト、パーシャルアゴニスト及びアンタゴニスト
TW201622746A (zh) 2014-04-24 2016-07-01 諾華公司 改善或加速髖部骨折術後身體復原之方法
KR20170017916A (ko) 2014-05-13 2017-02-15 추가이 세이야쿠 가부시키가이샤 면역 억제 기능을 갖는 세포에 대한 t 세포 리다이렉트 항원 결합 분자
JP2017515859A (ja) 2014-05-15 2017-06-15 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 抗ｐｄ−１抗体と他の抗癌剤の組み合わせを使用する肺癌の処置
LT3148579T (lt) 2014-05-28 2021-05-25 Agenus Inc. Anti-gitr antikūnai ir jų panaudojimo būdai
PL3151921T3 (pl) 2014-06-06 2020-02-28 Bristol-Myers Squibb Company Przeciwciała przeciwko receptorowi indukowanego glukokortykoidami czynnika martwicy nowotworu (gitr) i ich zastosowania
JP6997619B2 (ja) 2014-06-11 2022-01-17 キャシー・エイ・グリーン 液性免疫の抑制または増進のための、ｖｉｓｔａアゴニスト及びｖｉｓｔａアンタゴニストの使用
EP3161001A2 (en) 2014-06-25 2017-05-03 Novartis AG Antibodies specific for il-17a fused to hyaluronan binding peptide tags
US20170290876A1 (en) 2014-06-25 2017-10-12 Novartis Ag Compositions and methods for long acting proteins
US20170327553A1 (en) 2014-06-25 2017-11-16 Novartis Ag Compositions and methods for long acting proteins
EP3166688B1 (en) 2014-07-08 2024-08-21 New York University Tau imaging ligands and their uses in the diagnosis and treatment of tauopathy
ES2833425T3 (es) 2014-07-16 2021-06-15 Roussy Inst Gustave Combinación de virus oncolítico con moduladores de punto de control inmunitario
DK3552615T3 (da) 2014-07-16 2022-02-14 Transgene Onkolytisk virus til ekspression af immun-checkpoint-modulatorer
US20170226209A1 (en) 2014-08-01 2017-08-10 INSERM (Institut National de la Santé et de la Recherche Médicale) An anti-cd45rc antibody for use as drug
CN105296433B (zh) 2014-08-01 2018-02-09 中山康方生物医药有限公司 一种ctla4抗体、其药物组合物及其用途
US11219672B2 (en) 2014-08-07 2022-01-11 Haruki Okamura Therapeutic agent for cancer which comprises combination of IL-18 and molecule-targeting antibody
TW201613977A (en) 2014-08-07 2016-04-16 Novartis Ag Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
EA201790336A1 (ru) 2014-08-07 2017-06-30 Новартис Аг Антитела к ангиопоэтинподобному белку 4 и способы применения
CA2954463C (en) * 2014-08-08 2023-11-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Photo-controlled removal of targets in vitro and in vivo
EP3180018B1 (en) 2014-08-12 2019-07-24 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2 and integrin-binding-fc-fusion protein
WO2016025647A1 (en) 2014-08-12 2016-02-18 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2, a therapeutic antibody, and a cancer vaccine
EP3186281B1 (en) 2014-08-28 2019-04-10 Halozyme, Inc. Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor
EP3191126B1 (en) 2014-09-13 2020-05-13 Novartis AG Combination therapies of alk inhibitors
CA2944085C (en) 2014-09-16 2018-04-10 Ease Charm Limited Anti-egfr antibody and uses of same
CA2964155A1 (en) 2014-10-10 2016-04-14 Idera Pharmaceuticals, Inc. Treatment of cancer using tlr9 agonist with checkpoint inhibitors
AU2015332533B2 (en) 2014-10-14 2018-08-30 Halozyme, Inc. Compositions of adenosine deaminase-2 (ADA2), variants thereof and methods of using same
WO2016059220A1 (en) 2014-10-16 2016-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Tcr-activating agents for use in the treatment of t-all
CA2966201A1 (en) 2014-10-29 2016-05-06 Adaptive Biotechnologies Corp. Highly-multiplexed simultaneous detection of nucleic acids encoding paired adaptive immune receptor heterodimers from many samples
US10738078B2 (en) 2014-11-03 2020-08-11 Bristol-Myers Squibb Company Use of caprylic acid precipitation for protein purification
SI3215530T1 (sl) 2014-11-07 2020-02-28 Sesen Bio, Inc. Izboljšana protitelesa IL-6
WO2016073894A1 (en) 2014-11-07 2016-05-12 Eleven Biotherapeutics, Inc. Therapeutic agents with increased ocular retention
US10077287B2 (en) 2014-11-10 2018-09-18 Bristol-Myers Squibb Company Tubulysin analogs and methods of making and use
US10246701B2 (en) 2014-11-14 2019-04-02 Adaptive Biotechnologies Corp. Multiplexed digital quantitation of rearranged lymphoid receptors in a complex mixture
JP6805142B2 (ja) 2014-11-21 2020-12-23 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃｄ７３に対する抗体およびその使用
ES2826566T3 (es) 2014-11-21 2021-05-18 Bristol Myers Squibb Co Anticuerpos que comprenden regiones constantes pesadas modificadas
JP6696982B2 (ja) 2014-11-26 2020-05-20 ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． Ｃｄ３および腫瘍抗原に結合するヘテロ二量体抗体
AU2015358462A1 (en) 2014-12-04 2017-07-27 Bristol-Myers Squibb Company Combination of anti-CS1 and anti-PD1 antibodies to treat cancer (myeloma)
MX2017007136A (es) 2014-12-05 2017-12-04 Immunext Inc Identificacion de vsig8 como el receptor vista putativo y su uso para producir moduladores vista/vsig8.
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
US20170360857A1 (en) 2014-12-18 2017-12-21 Amgen Inc. Stable Frozen Virus Formulation
UY36449A (es) 2014-12-19 2016-07-29 Novartis Ag Composiciones y métodos para anticuerpos dirigidos a bmp6
AR103268A1 (es) 2014-12-23 2017-04-26 Bristol Myers Squibb Co Anticuerpos contra tigit
CN104479019B (zh) * 2014-12-26 2020-07-21 上海复宏汉霖生物技术股份有限公司 一种抗ctla-4人源抗体
HUE053145T2 (hu) 2014-12-31 2021-06-28 Checkmate Pharmaceuticals Inc Kombinált tumor immunterápia
CN107231804B (zh) 2015-01-14 2019-11-26 百时美施贵宝公司 亚杂芳基桥连苯并二氮杂*二聚体、其缀合物及制备和使用方法
MA41414A (fr) 2015-01-28 2017-12-05 Centre Nat Rech Scient Protéines de liaison agonistes d' icos
EP3250588A1 (en) 2015-01-29 2017-12-06 Board of Trustees of Michigan State University Cryptic polypeptides and uses thereof
CN114014930A (zh) 2015-02-13 2022-02-08 索伦托药业有限公司 结合ctla4的抗体治疗剂
CA2975432A1 (en) 2015-02-13 2016-08-18 Transgene Sa Immunotherapeutic vaccine and antibody combination therapy
WO2016138122A1 (en) 2015-02-24 2016-09-01 Adaptive Biotechnologies Corp. Methods for diagnosing infectious disease and determining hla status using immune repertoire sequencing
US9139653B1 (en) 2015-04-30 2015-09-22 Kymab Limited Anti-human OX40L antibodies and methods of treatment
BR112017018365A2 (pt) 2015-03-13 2018-04-10 Bristol-Myers Squibb Company uso de lavagens alcalinas durante cromatografia para remoção de impurezas
WO2016146143A1 (en) 2015-03-16 2016-09-22 Amal Therapeutics Sa Cell penetrating peptides and complexes comprising the same
US10196445B1 (en) 2015-03-17 2019-02-05 Bristol-Myers Squibb Company Ipilimumab variant with enhanced ADCC
US20180105555A1 (en) 2015-03-20 2018-04-19 Bristol-Myers Squibb Company Use of dextran for protein purification
US20180105554A1 (en) 2015-03-20 2018-04-19 Bristol-Myers Squibb Company Use of dextran sulfate to enhance protein a affinity chromatography
MA53297A (fr) 2015-03-23 2022-05-04 Jounce Therapeutics Inc Anticorps anti-icos
WO2016154629A1 (en) 2015-03-26 2016-09-29 Woman & Infants' Hospital Of Rhode Island Therapy for malignant disease
EP3277294B1 (en) 2015-04-01 2024-05-15 Adaptive Biotechnologies Corp. Method of identifying human compatible t cell receptors specific for an antigenic target
AU2016244570B2 (en) 2015-04-07 2020-08-27 Nec Corporation Medicine
US11215616B2 (en) 2015-04-10 2022-01-04 National Institutes Of Health (Nih), (Dhhs), U.S. Government Methods of determining patient populations amenable to immunomodulatory treatment of cancer
HRP20201334T1 (hr) 2015-04-17 2020-11-27 Bristol-Myers Squibb Company Kompozicije koje sadrže kombinaciju ipilimumaba i nivolumaba
DE112016001820B4 (de) 2015-04-20 2023-04-27 Mitsubishi Electric Corporation Laservorrichtung und licht-erzeugungsvorrichtung für extrem ultraviolette strahlung
WO2016176503A1 (en) 2015-04-28 2016-11-03 Bristol-Myers Squibb Company Treatment of pd-l1-negative melanoma using an anti-pd-1 antibody and an anti-ctla-4 antibody
EP3288980B1 (en) 2015-04-28 2021-03-10 Bristol-Myers Squibb Company Treatment of pd-l1-positive melanoma using an anti-pd-1 antibody
WO2016177682A1 (en) 2015-05-06 2016-11-10 Snipr Technologies Limited Altering microbial populations & modifying microbiota
WO2016183183A1 (en) 2015-05-11 2016-11-17 The Johns Hopkins University Autoimmune antibodies for use in inhibiting cancer cell growth
EP3297672B1 (en) 2015-05-21 2021-09-01 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
CN107921126A (zh) 2015-05-22 2018-04-17 转化药物开发有限责任公司 苯甲酰胺和活性化合物的组合物及其使用方法
WO2016191751A1 (en) 2015-05-28 2016-12-01 Bristol-Myers Squibb Company Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody
WO2016196389A1 (en) 2015-05-29 2016-12-08 Bristol-Myers Squibb Company Treatment of renal cell carcinoma
AU2016271111B2 (en) 2015-05-29 2022-04-28 Bristol-Myers Squibb Company Antibodies against OX40 and uses thereof
DK3303394T3 (da) 2015-05-29 2020-07-06 Agenus Inc Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf
WO2016196935A1 (en) 2015-06-03 2016-12-08 Boston Biomedical, Inc. Compositions comprising a cancer stemness inhibitor and an immunotherapeutic agent for use in treating cancer
SG11201707815RA (en) 2015-06-05 2017-12-28 Novartis Ag Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor
EP3722314A1 (en) 2015-06-24 2020-10-14 Janssen Pharmaceutica NV Anti-vista antibodies and fragments
DK3313528T3 (da) 2015-06-29 2021-09-20 Bristol Myers Squibb Co Immunterapeutiske doseringsskemaer omfattende pomalidomid og et anti-cs1-antistof til behandling af cancer
MX2017016502A (es) 2015-06-29 2018-03-12 Univ Rockefeller Anticuerpos contra cd40 con actividad agonista mejorada.
KR20180023968A (ko) 2015-07-02 2018-03-07 셀진 코포레이션 혈액암 및 충실성 종양의 치료를 위한 병용 요법
WO2017004538A1 (en) 2015-07-02 2017-01-05 Otsuka Pharmaceutical Co., Ltd. Lyophilized pharmaceutical compositions
GB201512203D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
GB201512215D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
DK3858859T3 (da) 2015-07-14 2025-12-15 Bristol Myers Squibb Co Fremgangsmåde til behandling af kræft under anvendelse af en immun checkpointinhibitor; antistof som binder til programmeret død-1 receptor (pd-1) eller programmeret død ligand 1 (pd-l1)
CA2991628C (en) 2015-07-16 2020-04-07 Bioxcel Therapeutics, Inc. A novel approach for treatment of cancer using immunomodulation
MX2017016844A (es) 2015-07-16 2018-08-15 Biokine Therapeutics Ltd Composiciones y procedimientos para tratar cancer.
US20180340025A1 (en) 2015-07-29 2018-11-29 Novartis Ag Combination therapies comprising antibody molecules to lag-3
WO2017023753A1 (en) 2015-07-31 2017-02-09 University Of Florida Research Foundation, Inc. Hematopoietic stem cells in combinatorial therapy with immune checkpoint inhibitors against cancer
EP3331914A1 (en) 2015-08-03 2018-06-13 Novartis AG Methods of treating fgf21-associated disorders
EP3331917A1 (en) 2015-08-04 2018-06-13 GlaxoSmithKline Intellectual Property Development Limited Combination treatments and uses and methods thereof
EP3331919A1 (en) 2015-08-07 2018-06-13 GlaxoSmithKline Intellectual Property Development Limited Combination therapy comprising anti ctla-4 antibodies
WO2017025918A1 (en) * 2015-08-11 2017-02-16 Novartis Ag 5-bromo-2,6-di-(lh-pyrazol-l-yl)pyrimidin-4-amine for use in the treatment of cancer
PT3334761T (pt) 2015-08-13 2023-08-17 Univ New York Moléculas baseadas em anticorpo seletivo para o epítopo {p}ser404 da tau e os seus usos no diagnóstico e tratamento de tauopatias
US11385231B2 (en) 2015-08-27 2022-07-12 Inserm (Institut National De La Sante Et De La Recherche Scientifique) Methods for predicting the survival time of patients suffering from a lung cancer
JP6869987B2 (ja) 2015-09-01 2021-05-12 アジェナス インコーポレイテッド 抗ｐｄ−１抗体及びその使用方法
SG11201801699VA (en) * 2015-09-03 2018-04-27 Ono Pharmaceutical Co Immunity enhancing agent for cancer by allergin-1 antagonist
EP3842457A1 (en) 2015-09-09 2021-06-30 Novartis AG Thymic stromal lymphopoietin (tslp)-binding molecules and methods of using the molecules
EA038332B1 (ru) 2015-09-09 2021-08-10 Новартис Аг Молекулы, связывающиеся с тимусным стромальным лимфопоэтином (tslp), и способы применения таких молекул
JP2018531625A (ja) 2015-09-11 2018-11-01 ナセント バイオテック インコーポレイテッド 脳への向上した薬物送達の方法
RU2638457C2 (ru) 2015-09-28 2017-12-13 Общество С Ограниченной Ответственностью "Онкомакс" Антитела, специфически связывающие рецептор 1 типа фактора роста фибробластов, применение антител для лечения онкологического заболевания, способ получения антител
WO2017055320A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of cytotoxic lymphocytes in a tissue sample
WO2017055319A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of b cells in a tissue sample
WO2017055321A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of fibroblasts in a tissue sample
WO2017055324A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of cells of monocytic origin in a tissue sample
WO2017055327A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of endothelial cells in a tissue sample
WO2017055322A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of neutrophils in a tissue sample
WO2017055326A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of myeloid dendritic cells in a tissue sample
WO2017055325A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of nk cells in a tissue sample
PT3355913T (pt) 2015-09-30 2024-12-18 Igm Biosciences Inc Moléculas de ligação com cadeia j modificada
ES2819870T3 (es) * 2015-09-30 2021-04-19 Igm Biosciences Inc Moléculas de unión con cadena J modificada
WO2017060397A1 (en) 2015-10-09 2017-04-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival time of subjects suffering from melanoma metastases
JP6954648B2 (ja) 2015-10-19 2021-10-27 シージー オンコロジー， インコーポレイテッド 併用療法による固形腫瘍又はリンパ系腫瘍の治療方法
US10968277B2 (en) 2015-10-22 2021-04-06 Jounce Therapeutics, Inc. Gene signatures for determining ICOS expression
SI3370733T1 (sl) 2015-11-02 2021-11-30 Board Of Regents The University Of Texas System Postopek za aktivacijo CD40 in blokada imunske nadzorne točke
US20180320136A1 (en) 2015-11-03 2018-11-08 GlycoMimitics, Inc. Methods and compositions for the production of monoclonal antibodies, hematopoietic stem cells, and methods of using the same
US20190038713A1 (en) 2015-11-07 2019-02-07 Multivir Inc. Compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
US11072657B2 (en) 2015-11-18 2021-07-27 Bristol-Myers Squibb Company Treatment of lung cancer using a combination of an anti-PD-1 antibody and an anti-CTLA-4 antibody
EP3378488A4 (en) 2015-11-18 2019-10-30 Chugai Seiyaku Kabushiki Kaisha Method for enhancing humoral immune response
JP6931329B2 (ja) 2015-11-18 2021-09-01 中外製薬株式会社 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法
MX2018006072A (es) 2015-11-19 2018-08-01 Squibb Bristol Myers Co Anticuerpos contra receptor de factor de necrosis de tumor inducido por glucocorticoides (gitr) y usos de los mismos.
WO2017084078A1 (en) * 2015-11-19 2017-05-26 Zeling Cai Ctla-4 antibodies and uses thereof
EP3383920B1 (en) 2015-11-30 2024-01-10 The Regents of the University of California Tumor-specific payload delivery and immune activation using a human antibody targeting a highly specific tumor cell surface antigen
US10556948B2 (en) 2015-11-30 2020-02-11 Bristol-Myers Squibb Company IP-10 antibodies and their uses
ES2913208T3 (es) 2015-12-01 2022-06-01 Glaxosmithkline Ip Dev Ltd Tratamientos de combinación y usos y métodos de los mismos
WO2017096179A1 (en) 2015-12-02 2017-06-08 Agenus Inc. Antibodies and methods of use thereof
JP6411676B2 (ja) 2015-12-03 2018-10-24 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Ｓｔｉｎｇの調節因子としての環状プリンジヌクレオチド
EP3387013B1 (en) 2015-12-07 2022-06-08 Xencor, Inc. Heterodimeric antibodies that bind cd3 and psma
WO2017098421A1 (en) 2015-12-08 2017-06-15 Glaxosmithkline Intellectual Property Development Limited Benzothiadiazine compounds
US11286307B2 (en) 2015-12-11 2022-03-29 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
CN108367069B (zh) * 2015-12-14 2022-08-23 宏观基因有限公司 对于pd-1和ctla-4具有免疫反应性的双特异性分子及其使用方法
CN108495651A (zh) 2015-12-17 2018-09-04 诺华股份有限公司 抗pd-1的抗体分子及其用途
TW201731872A (zh) 2015-12-18 2017-09-16 諾華公司 標靶CD32b之抗體及其使用方法
EP3394096A1 (en) 2015-12-21 2018-10-31 Bristol-Myers Squibb Company Variant antibodies for site-specific conjugation
SMT202200310T1 (it) 2015-12-23 2022-09-14 Modernatx Inc Metodi di utilizzo dei polinucleotidi codificanti il ligando di ox40
CA3010794A1 (en) 2016-01-08 2017-07-13 Celgene Corporation Solid forms of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide, and their pharmaceutical compositions and uses
TWI782395B (zh) 2016-01-08 2022-11-01 美商西建公司 抗增生化合物，及其醫藥組合物及用途
US10052315B2 (en) 2016-01-08 2018-08-21 Celgene Corporation Formulations of 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
US20190241658A1 (en) * 2016-01-10 2019-08-08 Modernatx, Inc. Therapeutic mRNAs encoding anti CTLA-4 antibodies
CA2954892A1 (en) 2016-01-19 2017-07-19 Pfizer Inc. Immunogens derived from tumor-associated antigens or nucleic acid molecules encoding the immunogens
EP3851457A1 (en) 2016-01-21 2021-07-21 Novartis AG Multispecific molecules targeting cll-1
JP6970099B2 (ja) 2016-01-28 2021-11-24 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル ガンの処置のための方法及び医薬組成物
JP6902040B2 (ja) 2016-01-28 2021-07-14 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 免疫チェックポイント阻害剤の効力を増強する方法
US10899836B2 (en) 2016-02-12 2021-01-26 Janssen Pharmaceutica Nv Method of identifying anti-VISTA antibodies
BR112018017031A2 (pt) 2016-02-23 2019-01-22 Sesen Bio Inc formulações de antagonista de il-6 e usos das mesmas
CA3013333A1 (en) 2016-02-26 2017-08-31 Inserm (Institut National De La Sante Et De La Recherche Medicale) Antibodies having specificity for btla and uses thereof
AU2017228470A1 (en) 2016-03-04 2018-08-30 Bristol-Myers Squibb Company Combination therapy with anti-CD73 antibodies
CN116063494A (zh) 2016-03-04 2023-05-05 洛克菲勒大学 具有增强的激动剂活性的cd40的抗体
WO2017153952A1 (en) 2016-03-10 2017-09-14 Glaxosmithkline Intellectual Property Development Limited 5-sulfamoyl-2-hydroxybenzamide derivatives
US11497781B2 (en) 2016-03-10 2022-11-15 Cg Oncology, Inc. Methods of treating bladder cancer by combination therapy comprising the oncolytic adenovirus CG0070 and an immune checkpoint inhibitor
WO2017160599A1 (en) 2016-03-14 2017-09-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of cd300b antagonists to treat sepsis and septic shock
BR112018068461A2 (pt) 2016-03-15 2019-01-22 Mersana Therapeutics Inc conjugado, composição farmacêutica, métodos para preparação de um conjugado e para alívio de um sintoma de um câncer.
EP3429618B1 (en) 2016-03-16 2024-02-21 Amal Therapeutics SA Combination of an immune checkpoint modulator and a complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist for use in medicine
MA44483A (fr) 2016-03-24 2019-01-30 Millennium Pharm Inc Procédés pour traiter des événements indésirables gastro-intestinaux d'origine immunitaire dans des traitements oncologiques immunitaires
TW201735949A (zh) 2016-03-24 2017-10-16 千禧製藥公司 治療抗ctla4及抗pd-1組合治療中的胃腸道免疫相關不良事件之方法
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
WO2017173091A1 (en) 2016-03-30 2017-10-05 Musc Foundation For Research Development Methods for treatment and diagnosis of cancer by targeting glycoprotein a repetitions predominant (garp) and for providing effective immunotherapy alone or in combination
US11209441B2 (en) 2016-04-05 2021-12-28 Bristol-Myers Squibb Company Cytokine profiling analysis
SG10201900628RA (en) 2016-04-07 2019-02-27 Glaxosmithkline Ip Dev Ltd Heterocyclic amides useful as protein modulators
WO2017175156A1 (en) 2016-04-07 2017-10-12 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators
EP3443013B1 (en) 2016-04-14 2025-01-22 Creatv Microtech, Inc. Methods of using pd-l1 expression in treatment decisions for cancer therapy
PE20190115A1 (es) 2016-04-15 2019-01-16 Immunext Inc Anticuerpos vista antihumanos y su uso
BR112018071307A2 (pt) 2016-04-18 2019-02-26 Celldex Therapeutics, Inc. anticorpos agonistas que ligam cd40 humana e usos dos mesmos
KR102323872B1 (ko) 2016-04-22 2021-11-08 임비라 컴퍼니 리미티드 암치료용 종양 용해성 단순 헤르페스 바이러스(oHSV) 절대 벡터 및 그 구조체의 구조
CA3022377A1 (en) 2016-04-29 2017-11-02 Board Of Regents, The University Of Texas System Targeted measure of transcriptional activity related to hormone receptors
WO2017192874A1 (en) 2016-05-04 2017-11-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Albumin-binding immunomodulatory compositions and methods of use thereof
US10968279B2 (en) 2016-05-09 2021-04-06 Bristol-Myers Squibb Company TL1A antibodies and uses thereof
JP2019518013A (ja) 2016-05-10 2019-06-27 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 安定性が向上したツブリシン類似体の抗体薬物結合体
SG10201603721TA (en) 2016-05-10 2017-12-28 Agency Science Tech & Res Anti-CTLA-4 Antibodies
CA3024509A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Mrna combination therapy for the treatment of cancer
PL3458083T3 (pl) 2016-05-18 2023-03-13 Modernatx, Inc. Polinukleotydy kodujące interleukinę-12 (il12) i ich zastosowania
RS63625B1 (sr) 2016-05-18 2022-10-31 Modernatx Inc Kombinacije irnk koje kodiraju imunomodulirajuće polipeptide i njihova upotreba
US12202856B2 (en) 2016-05-19 2025-01-21 The General Hospital Corporation Tethered interleukin-2 to its receptor IL-2RBETA, a platform to enhance natural killer and regulatory T cell activity
CN107400166A (zh) * 2016-05-19 2017-11-28 苏州康宁杰瑞生物科技有限公司 针对ctla4的单域抗体及其衍生蛋白
HRP20220237T1 (hr) 2016-05-20 2022-04-29 Biohaven Therapeutics Ltd. Primjena riluzola, prolijekova riluzola ili analoga riluzola sa imunoterapijama za liječenje raka
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
KR102530742B1 (ko) 2016-05-20 2023-05-09 하푼 테라퓨틱스, 인크. 단일 도메인 혈청 알부민 결합 단백질
RU2741786C2 (ru) 2016-05-25 2021-01-28 Энсэрм (Энститю Насьональ Де Ла Санте Э Де Ла Решерш Медикаль) Способы и композиции для лечения опухолей
US11052148B2 (en) 2016-05-30 2021-07-06 Geo Vax, Inc. Compositions and methods for generating an immune response to hepatitis B virus
WO2017210335A1 (en) 2016-06-01 2017-12-07 Bristol-Myers Squibb Company Imaging methods using 18f-radiolabeled biologics
HUE062398T2 (hu) 2016-06-02 2023-10-28 Bristol Myers Squibb Co PD-1 blokád nivolumabbal refrakter Hodgkin limfómában
KR102976378B1 (ko) 2016-06-03 2026-06-11 브리스톨-마이어스 스큅 컴퍼니 결장직장암을 갖는 환자의 치료에서의 항-pd-1 항체의 용도
WO2017210631A1 (en) 2016-06-03 2017-12-07 Bristol-Myers Squibb Company Anti-pd-1 antibody for use in a method of treatment of recurrent small cell lung cancer
GB201609811D0 (en) 2016-06-05 2016-07-20 Snipr Technologies Ltd Methods, cells, systems, arrays, RNA and kits
CA3026983A1 (en) 2016-06-08 2017-12-14 Glaxosmithkline Intellectual Property Development Limited Chemical compounds
RU2018145734A (ru) 2016-06-08 2020-07-14 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Химические соединения в качестве ингибиторов atf4 пути
CN109715196A (zh) 2016-06-13 2019-05-03 转矩医疗股份有限公司 用于促进免疫细胞功能的组合物和方法
CA3026151A1 (en) 2016-06-14 2017-12-21 Xencor, Inc. Bispecific checkpoint inhibitor antibodies
WO2017216724A1 (en) 2016-06-15 2017-12-21 Novartis Ag Methods for treating disease using inhibitors of bone morphogenetic protein 6 (bmp6)
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
EP3474856B1 (en) 2016-06-24 2022-09-14 Infinity Pharmaceuticals, Inc. Combination therapies
EP3478321A4 (en) 2016-06-30 2020-04-22 Oncorus, Inc. PSEUDOTYPIZED ONCOLYTIC VIRAL ADMINISTRATION OF THERAPEUTIC POLYPEPTIDES
JP7029415B2 (ja) 2016-07-12 2022-03-03 ハー・ルンドベック・アクチエゼルスカベット 過リン酸化タウに特異的な抗体およびその使用方法
WO2018011166A2 (en) 2016-07-12 2018-01-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of myeloid dendritic cells in a tissue sample
US20190233534A1 (en) 2016-07-14 2019-08-01 Fred Hutchinson Cancer Research Center Multiple bi-specific binding domain constructs with different epitope binding to treat cancer
US20190248893A1 (en) 2016-07-14 2019-08-15 Bristol-Myers Squibb Company Antibodies against tim3 and uses thereof
CN109789135A (zh) 2016-07-20 2019-05-21 葛兰素史密斯克莱知识产权发展有限公司 作为perk抑制剂的异喹啉衍生物
WO2018014260A1 (en) 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
EP3490561A4 (en) * 2016-08-01 2020-04-08 Ignyta, Inc. COMBINATIONS FOR TREATING CANCER
NL2017270B1 (en) * 2016-08-02 2018-02-09 Aduro Biotech Holdings Europe B V New anti-hCTLA-4 antibodies
EP3494140A1 (en) 2016-08-04 2019-06-12 GlaxoSmithKline Intellectual Property Development Ltd Anti-icos and anti-pd-1 antibody combination therapy
CN109562153A (zh) 2016-08-07 2019-04-02 诺华股份有限公司 mRNA介导的免疫方法
RU2764548C2 (ru) 2016-08-09 2022-01-18 Кимаб Лимитед Анти-icos антитела
WO2018029336A1 (en) 2016-08-12 2018-02-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for determining whether a subject was administered with an activator of the ppar beta/delta pathway.
JP2019530646A (ja) 2016-08-12 2019-10-24 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ タンパク質精製法
WO2018035391A1 (en) 2016-08-19 2018-02-22 Bristol-Myers Squibb Company Seco-cyclopropapyrroloindole compounds, antibody-drug conjugates thereof, and methods of making and use
CN110087680B (zh) 2016-08-19 2024-03-19 百济神州有限公司 使用包含btk抑制剂的组合产品治疗癌症
WO2018035710A1 (en) 2016-08-23 2018-03-01 Akeso Biopharma, Inc. Anti-ctla4 antibodies
WO2018044970A1 (en) 2016-08-31 2018-03-08 University Of Rochester Human monoclonal antibodies to human endogenous retrovirus k envelope (herv-k) and uses thereof
WO2018046736A1 (en) 2016-09-12 2018-03-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival time of patients suffering from cancer
WO2018046738A1 (en) 2016-09-12 2018-03-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival time of patients suffering from cancer
EP3515489B1 (en) 2016-09-19 2025-11-05 OncoC4, Inc. Cd80 and cd86 binding protein compositions and uses thereof
KR20190057345A (ko) 2016-09-21 2019-05-28 아말 테라퓨틱스 에스에이 암 치료를 위한, 세포 투과 펩타이드, 멀티 에피토프 및 tlr 펩타이드 작용제를 포함하는 융합체
US10428325B1 (en) 2016-09-21 2019-10-01 Adaptive Biotechnologies Corporation Identification of antigen-specific B cell receptors
EP3515453A1 (en) 2016-09-22 2019-07-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for reprograming immune environment in a subject in need thereof
EP3515951B1 (en) 2016-09-23 2024-02-28 Merus N.V. Binding molecules that modulate a biological activity expressed by a cell
EP3518946A4 (en) 2016-09-27 2020-09-09 Board of Regents, The University of Texas System METHODS TO IMPROVE IMMUNE CHECKPOINT BLOCKING TREATMENT BY MODULATING THE MICROBIOME
CA3036714A1 (en) 2016-10-03 2018-04-12 Abbott Laboratories Improved methods of assessing uch-l1 status in patient samples
JP6976322B2 (ja) * 2016-10-10 2021-12-08 クラウン バイオサイエンス，インコーポレイテッド（タイツァン） 新規抗ｃｔｌａ４抗体
KR20230133934A (ko) 2016-10-11 2023-09-19 아게누스 인코포레이티드 항-lag-3 항체 및 이의 사용 방법
US11291718B2 (en) 2016-10-11 2022-04-05 Cytlimic Inc. Method for treating cancer by administering a toll-like receptor agonist and LAG-3 IgG fusion protein
WO2018068201A1 (en) * 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against ctla-4
WO2018071668A1 (en) 2016-10-12 2018-04-19 Board Of Regents, The University Of Texas System Methods and compositions for tusc2 immunotherapy
US10398783B2 (en) 2016-10-20 2019-09-03 Bristol-Myers Squibb Company Antiproliferative compounds and conjugates made therefrom
KR102634093B1 (ko) 2016-10-28 2024-02-07 브리스톨-마이어스 스큅 컴퍼니 항-pd-1 항체를 사용하여 요로상피 암종을 치료하는 방법
CN110072890B (zh) 2016-11-03 2022-11-29 百时美施贵宝公司 可活化的抗ctla-4抗体及其用途
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
EP3534933B1 (en) 2016-11-04 2025-01-01 Aximmune, Inc. Beta-alethine in combination with immune modulators and uses thereof
JP2019534044A (ja) 2016-11-08 2019-11-28 クイル ピュージェット サウンド バイオセラピューティクス コーポレーション 抗ｐｄ１および抗ｃｔｌａ４抗体
US11883430B2 (en) 2016-11-09 2024-01-30 Musc Foundation For Research Development CD38-NAD+ regulated metabolic axis in anti-tumor immunotherapy
CA3041340A1 (en) 2016-11-09 2018-05-17 Agenus Inc. Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof
EP3538551A4 (en) 2016-11-10 2020-11-11 Fortis Therapeutics, Inc. CD46 SPECIFIC EFFECTOR CELLS AND USES THEREOF
CN109996809A (zh) 2016-11-14 2019-07-09 诺华股份有限公司 与促融合蛋白minion相关的组合物、方法和治疗用途
EP3538140A1 (en) 2016-11-14 2019-09-18 Institut National de la Sante et de la Recherche Medicale (INSERM) Methods and pharmaceutical compositions for modulating stem cells proliferation or differentiation
RU2019114679A (ru) 2016-11-15 2020-12-17 Х. Лундбекк А/С Средства, пути применения и способы лечения синуклеопатии
BR112019010020A2 (pt) 2016-11-17 2019-08-20 Univ Texas compostos com atividade anti-tumoral contra células cancerosas contendo mutações de egfr ou her2 exon 20
WO2018098352A2 (en) 2016-11-22 2018-05-31 Jun Oishi Targeting kras induced immune checkpoint expression
US11135307B2 (en) 2016-11-23 2021-10-05 Mersana Therapeutics, Inc. Peptide-containing linkers for antibody-drug conjugates
US10780080B2 (en) 2016-11-23 2020-09-22 Translational Drug Development, Llc Benzamide and active compound compositions and methods of use
CN106432499A (zh) * 2016-11-24 2017-02-22 上海美迪西生物医药股份有限公司 Ctla‑4抗体fab在昆虫表达系统中的制备方法
WO2018099539A1 (en) 2016-11-29 2018-06-07 Horst Lindhofer Combination of t-cell redirecting multifunctional antibodies with immune checkpoint modulators and uses thereof
CA3045306A1 (en) 2016-11-29 2018-06-07 Boston Biomedical, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
EP3548069A1 (en) 2016-12-01 2019-10-09 GlaxoSmithKline Intellectual Property Development Limited Combination therapy
WO2018100535A1 (en) 2016-12-01 2018-06-07 Glaxosmithkline Intellectual Property Development Limited Combination therapy
IL307242B1 (en) * 2016-12-07 2026-07-01 Agenus Inc Anti-CTLA-4 antibodies and methods of using them
KR102209364B1 (ko) 2016-12-09 2021-02-01 리제너론 파아마슈티컬스, 인크. T 세포 수용체를 시퀀싱하기 위한 시스템 및 방법 및 이의 용도
JPWO2018110515A1 (ja) 2016-12-12 2019-10-24 第一三共株式会社 抗体−薬物コンジュゲートと免疫チェックポイント阻害剤の組み合わせ
WO2018111902A1 (en) 2016-12-12 2018-06-21 Multivir Inc. Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases
US20200095301A1 (en) 2016-12-14 2020-03-26 The Board Of Trustees Of The Leland Stanford Junior University Il-13 superkine: immune cell targeting constructs and methods of use thereof
EP3555127B1 (en) 2016-12-16 2024-12-18 H. Lundbeck A/S Agents, uses and methods
WO2018112360A1 (en) 2016-12-16 2018-06-21 Evelo Biosciences, Inc. Combination therapies for treating cancer
US10364286B2 (en) 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
JP2020501589A (ja) 2016-12-23 2020-01-23 ウイルツ・バイオロジクス・リミテッド がんの治療
EP3559029A2 (en) 2016-12-23 2019-10-30 Bristol-Myers Squibb Company Design of therapeutic immunoglobulin g4 for improved bioanalytical and bioprocessing properties
WO2018122245A1 (en) 2016-12-28 2018-07-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting the survival time of patients suffering from cms3 colorectal cancer
WO2018122249A1 (en) 2016-12-28 2018-07-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival time of patients suffering from a microsatellite stable colorectal cancer
US10995137B2 (en) 2017-01-04 2021-05-04 H. Lundbeck A/S Antibodies specific for hyperphosphorlated tau for the treatment of ocular diseases
TW201833140A (zh) 2017-01-09 2018-09-16 美商莫瑞麥克製藥公司 抗fgfr抗體及使用方法
EP3568150A4 (en) 2017-01-10 2020-12-02 Xcella Biosciences, Inc. POLYTHERAPY FOR TUMOR TREATMENT WITH INTEGRIN-BOUND FC FUSION PROTEIN AND IMMUNE MODULATOR
US10350266B2 (en) 2017-01-10 2019-07-16 Nodus Therapeutics, Inc. Method of treating cancer with a multiple integrin binding Fc fusion protein
JP7062010B2 (ja) 2017-01-27 2022-05-02 セルジーン コーポレイション ３－（１－オキソ－４－（（４－（（３－オキソモルホリノ）メチル）ベンジル）オキシ）イソインドリン－２－イル）ピペリジン－２，６－ジオン及びそのアイソトポログ
WO2018148381A1 (en) 2017-02-07 2018-08-16 Nantcell, Inc. Maximizing t-cell memory and compositions and methods therefor
WO2018146128A1 (en) 2017-02-07 2018-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Detection of kit polymorphism for predicting the response to checkpoint blockade cancer immunotherapy
WO2018146148A1 (en) 2017-02-07 2018-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) A method for predicting the response to checkpoint blockade cancer immunotherapy
CA3052911A1 (en) 2017-02-08 2018-08-16 Novartis Ag Fgf21 mimetic antibodies and uses thereof
TWI674261B (zh) 2017-02-17 2019-10-11 美商英能腫瘤免疫股份有限公司 Nlrp3 調節劑
JP7136790B2 (ja) 2017-02-17 2022-09-13 ブリストル－マイヤーズ スクイブ カンパニー アルファ－シヌクレインに対する抗体およびその使用
CN110612447B (zh) 2017-02-24 2024-02-06 德克萨斯州立大学董事会 用于检测早期胰腺癌的测定
EP3585782A1 (en) 2017-02-27 2020-01-01 GlaxoSmithKline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors
SG11201907867TA (en) * 2017-02-28 2019-09-27 Bristol Myers Squibb Co Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine
EP3366703B1 (en) 2017-02-28 2019-04-03 Ralf Kleef Immune checkpoint therapy with hyperthermia
TW201834697A (zh) 2017-02-28 2018-10-01 美商梅爾莎納醫療公司 Her2標靶抗體－藥物結合物之組合療法
WO2018167778A1 (en) 2017-03-12 2018-09-20 Yeda Research And Development Co. Ltd. Methods of diagnosing and prognosing cancer
WO2018167780A1 (en) 2017-03-12 2018-09-20 Yeda Research And Development Co. Ltd. Methods of prognosing and treating cancer
WO2018170133A1 (en) 2017-03-15 2018-09-20 Amgen Inc. Use of oncolytic viruses, alone or in combination with a checkpoint inhibitor, for the treatment of cancer
CN106916226B (zh) * 2017-03-17 2020-01-14 信达生物制药(苏州)有限公司 以ctla-4为靶点的免疫调节药物治疗结核病的应用
JP7346300B2 (ja) 2017-03-23 2023-09-19 アボット・ラボラトリーズ 早期バイオマーカーであるユビキチンカルボキシ末端ヒドロラーゼｌ１を使用する、ヒト対象における外傷性脳損傷の程度の診断及び決定の一助となるための方法
KR102628323B1 (ko) 2017-03-24 2024-01-22 노바르티스 아게 심장질환 예방 및 치료 방법
US11359005B2 (en) 2017-03-30 2022-06-14 The Johns Hopkins University Supramolecular high affinity protein-binding system for purification of biomacromolecules
EP3601355A1 (en) 2017-03-31 2020-02-05 Bristol-Myers Squibb Company Methods of treating tumor
KR20200020662A (ko) 2017-04-03 2020-02-26 온콜로지, 인크. 면역-종양학 제제와 함께 ps-표적화 항체를 사용하여 암을 치료하는 방법
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
EP3610026B1 (en) 2017-04-14 2025-05-14 CG Oncology, Inc. Cg0070 for treating bcg resistant bladder carcinoma in situ
EP3610268B1 (en) 2017-04-15 2025-09-24 Abbott Laboratories Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury in a human subject using early biomarkers
JP2020517259A (ja) 2017-04-19 2020-06-18 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 操作された抗原受容体を発現する免疫細胞
CN118892540A (zh) 2017-04-21 2024-11-05 新罗杰股份有限公司 溶瘤痘苗病毒与免疫检查点抑制剂联合疗法
JP2020517699A (ja) 2017-04-26 2020-06-18 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ジスルフィド結合の還元を最小限にする抗体製造法
JP7080899B2 (ja) 2017-04-28 2022-06-06 アボット・ラボラトリーズ 同じヒト対象に由来する少なくとも２つの試料に対して早期バイオマーカーを使用する、外傷性脳損傷の超急性の診断及び決定の一助となるための方法
MX2019012741A (es) 2017-04-28 2020-01-21 Merck Sharp & Dohme Biomarcadores para agentes terapeuticos contra el cancer.
CA3060695A1 (en) 2017-05-02 2018-11-08 Merck Sharp & Dohme Corp. Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
US10865238B1 (en) 2017-05-05 2020-12-15 Duke University Complement factor H antibodies
SG10202107880XA (en) 2017-05-12 2021-09-29 Harpoon Therapeutics Inc Mesothelin binding proteins
JP2020520923A (ja) 2017-05-17 2020-07-16 ボストン バイオメディカル， インコーポレイテッド がんを処置するための方法
AU2018270111B2 (en) 2017-05-18 2022-07-14 Modernatx, Inc. Polynucleotides encoding tethered interleukin-12 (IL12) polypeptides and uses thereof
IL270743B2 (en) * 2017-05-19 2024-09-01 Wuxi Biologics Shanghai Co Ltd Monoclonal antibodies to cytotoxic t-lymphocyte-associated protein 4 (ctla-4), compositions containing same and uses thereof
KR102920712B1 (ko) 2017-05-24 2026-01-30 노파르티스 아게 항체-사이토카인 생착된 단백질 및 암 치료에 있어서의 사용 방법
US10866251B2 (en) 2017-05-25 2020-12-15 Abbott Laboratories Methods for aiding in the determination of whether to perform imaging on a human subject who has sustained or may have sustained an injury to the head using early biomarkers
MX2019013132A (es) 2017-05-25 2020-01-27 Bristol Myers Squibb Co Anticuerpos que comprenden regiones constantes pesadas modificadas.
WO2018222783A1 (en) 2017-05-30 2018-12-06 Abbott Laboratories Methods for aiding in diagnosing and evaluating a mild traumatic brain injury in a human subject using cardiac troponin i and early biomarkers
JP7301002B2 (ja) 2017-05-30 2023-06-30 ブリストル－マイヤーズ スクイブ カンパニー 抗ｌａｇ－３抗体または抗ｌａｇ－３抗体および抗ｐｄ－１もしくは抗ｐｄ－ｌ１抗体を含む組成物
WO2018222718A1 (en) 2017-05-30 2018-12-06 Bristol-Myers Squibb Company Treatment of lag-3 positive tumors
JP2020522495A (ja) 2017-05-30 2020-07-30 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 抗ｌａｇ−３抗体、ｐｄ−１経路阻害剤および免疫療法剤の組み合わせを含む組成物
CN110730777A (zh) 2017-06-07 2020-01-24 葛兰素史密斯克莱知识产权发展有限公司 作为atf4通路抑制剂的化学化合物
ES3000510T3 (en) 2017-06-09 2025-02-28 Providence Health & Services Oregon Tumor-infiltrating t-cells for use in the treatment of cancer
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
AU2018287317B2 (en) 2017-06-19 2024-06-20 Medicenna Therapeutics Inc. Uses and methods for IL-2 superagonists, agonists, and fusions thereof
EP3641739A1 (en) 2017-06-20 2020-04-29 Institut Curie Inhibitor of suv39h1 histone methyltransferase for use in cancer combination therapy
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
US20200172628A1 (en) 2017-06-22 2020-06-04 Novartis Ag Antibody molecules to cd73 and uses thereof
IL271491B2 (en) 2017-06-22 2023-09-01 Celgene Corp Treatment of carcinoma of the liver characterized by hepatitis b virus infection
MX2019015885A (es) 2017-06-22 2020-09-10 Novartis Ag Moleculas de anticuerpo que se unen a cd73 y usos de las mismas.
EP3645564A1 (en) 2017-06-28 2020-05-06 Novartis AG Methods for preventing and treating urinary incontinence
EP4201399A3 (en) 2017-06-30 2023-08-09 Celgene Corporation Compositions and methods of use of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl) -2,2-difluoroacetamide
EP3649108A1 (en) 2017-07-03 2020-05-13 GlaxoSmithKline Intellectual Property Development Limited 2-(4-chlorophenoxy)-n-((1 -(2-(4-chlorophenoxy)ethynazetidin-3-yl)methyl)acetamide derivatives and related compounds as atf4 inhibitors for treating cancer and other diseases
WO2019008506A1 (en) 2017-07-03 2019-01-10 Glaxosmithkline Intellectual Property Development Limited N- (3- (2- (4-CHLOROPHENOXY) ACETAMIDO) BICYCLO [1.1.1] PENTAN-1-YL) -2-CYCLOBUTANE-1-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ATF4 INHIBITORS FOR THE TREATMENT OF CANCER AND OTHER DISEASES
EP3649474A1 (en) 2017-07-03 2020-05-13 Abbott Laboratories Improved methods for measuring ubiquitin carboxy-terminal hydrolase l1 levels in blood
CN107325181A (zh) * 2017-07-05 2017-11-07 无锡傲锐东源生物科技有限公司 抗ctla4蛋白单克隆抗体及其用途
JP7258009B2 (ja) 2017-07-10 2023-04-14 セルジーン コーポレイション 抗増殖化合物及びその使用方法
RU2020100072A (ru) 2017-07-11 2021-08-11 Пфайзер Инк. Иммуногенные композиции, содержащие cea, muc1 и tert
ES3002968T3 (en) 2017-07-14 2025-03-10 Innate Tumor Immunity Inc Nlrp3 modulators
US10894833B2 (en) 2017-07-20 2021-01-19 H. Lundbeck A/S Agents, uses and methods for treatment
US11926664B2 (en) 2017-07-25 2024-03-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for modulating monocytopoiesis
WO2019021208A1 (en) 2017-07-27 2019-01-31 Glaxosmithkline Intellectual Property Development Limited USEFUL INDAZOLE DERIVATIVES AS PERK INHIBITORS
TWI799432B (zh) 2017-07-27 2023-04-21 美商再生元醫藥公司 抗ctla-4抗體及其用途
BR112020002280A2 (pt) 2017-08-03 2020-07-28 Otsuka Pharmaceutical Co., Ltd. composto farmacológico e métodos purificação do mesmo
US10487084B2 (en) 2017-08-16 2019-11-26 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor
US10457681B2 (en) 2017-08-16 2019-10-29 Bristol_Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor
US10472361B2 (en) 2017-08-16 2019-11-12 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor
US10508115B2 (en) 2017-08-16 2019-12-17 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor
WO2019036433A2 (en) * 2017-08-16 2019-02-21 Bristol-Myers Squibb Company ANTIBODIES IN THE FORM OF PRODRUGS, PRODRUGS BASED THEREON, THEIR METHODS OF USE AND PREPARATION
US10494370B2 (en) 2017-08-16 2019-12-03 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor
ES2977589T3 (es) 2017-08-18 2024-08-27 Cothera Bioscience Inc Forma polimórfica de TG02
JP7379323B2 (ja) 2017-08-18 2023-11-14 ザ・ジョンズ・ホプキンス・ユニバーシティ タンパク質精製のための超分子フィラメント集合体
CN111511762B (zh) 2017-08-21 2025-05-06 天演药业公司 抗cd137分子及其用途
UY37866A (es) 2017-09-07 2019-03-29 Glaxosmithkline Ip Dev Ltd Nuevos compuestos derivados de benzoimidazol sustituidos que reducen la proteína myc (c-myc) en las células e inhiben la histona acetiltransferasa de p300/cbp.
WO2019053617A1 (en) 2017-09-12 2019-03-21 Glaxosmithkline Intellectual Property Development Limited CHEMICAL COMPOUNDS
WO2019057744A1 (en) 2017-09-19 2019-03-28 Institut Curie AROMATIC HYDROCARBON RECEPTOR AGONIST FOR USE IN ASSOCIATION TREATMENT AGAINST CANCER
KR20200059243A (ko) 2017-09-20 2020-05-28 리제너론 파마슈티칼스 인코포레이티드 패신저 유전자 돌연변이 부담이 높은 종양을 가진 환자에 대한 면역 치료요법
US11351163B2 (en) 2017-09-29 2022-06-07 Bristol-Myers Squibb Company Compositions and methods of treating cancer
AU2018344902B2 (en) 2017-10-05 2021-06-03 Glaxosmithkline Intellectual Property Development Limited Modulators of stimulator of interferon genes (STING) useful in treating HIV
US11377440B2 (en) 2017-10-05 2022-07-05 Glaxosmithkline Intellectual Property Development Limited Modulators of stimulator of interferon genes (STING)
WO2019075385A1 (en) 2017-10-12 2019-04-18 Board Of Regents, The University Of Texas System T-LYMPHOCYTE COMPOSITIONS FOR IMMUNOTHERAPY
CA3078969A1 (en) 2017-10-13 2019-04-18 Harpoon Therapeutics, Inc. Trispecific proteins and methods of use
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
EP3694884A1 (en) 2017-10-15 2020-08-19 Bristol-Myers Squibb Company Methods of treating tumor
WO2019081983A1 (en) 2017-10-25 2019-05-02 Novartis Ag CD32B TARGETING ANTIBODIES AND METHODS OF USE
US11603410B2 (en) 2017-11-01 2023-03-14 Bristol-Myers Squibb Company Immunostimulatory agonistic antibodies for use in treating cancer
WO2019094360A1 (en) 2017-11-07 2019-05-16 The Board Of Regents Of The University Of Texas System Targeting lilrb4 with car-t or car-nk cells in the treatment of cancer
CN111315398A (zh) 2017-11-10 2020-06-19 阿尔莫生物科技股份有限公司 白介素-10与免疫检查点途径抑制剂的组合的组合物和使用方法
US11529344B2 (en) 2017-11-14 2022-12-20 Pfizer Inc. EZH2 inhibitor combination therapies
CA3082436A1 (en) 2017-11-16 2019-05-23 Board Of Regents, The University Of Texas System Methods for production of msc-derived exosomes
IL314506A (en) 2017-11-24 2024-09-01 Inst Nat Sante Rech Med Methods and preparations for the treatment of cancer
US11638760B2 (en) 2017-11-27 2023-05-02 Mersana Therapeutics, Inc. Pyrrolobenzodiazepine antibody conjugates
US11254980B1 (en) 2017-11-29 2022-02-22 Adaptive Biotechnologies Corporation Methods of profiling targeted polynucleotides while mitigating sequencing depth requirements
WO2019112860A1 (en) 2017-12-09 2019-06-13 Abbott Laboratories Methods for aiding in diagnosing and evaluating a traumatic brain injury in a human subject using a combination of gfap and uch-l1
WO2019113525A2 (en) 2017-12-09 2019-06-13 Abbott Laboratories Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (tbi), using glial fibrillary acidic protein (gfap) and/or ubiquitin carboxy-terminal hydrolase l1 (uch-l1)
EP3498293A1 (en) 2017-12-15 2019-06-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Treatment of monogenic diseases with an anti-cd45rc antibody
CA3084821A1 (en) 2017-12-15 2019-06-20 Board Of Regents, The University Of Texas System Methods and compositions for treating cancer using exosomes-associated gene editing
WO2019122882A1 (en) 2017-12-19 2019-06-27 Kymab Limited Bispecific antibody for icos and pd-l1
GB201721338D0 (en) 2017-12-19 2018-01-31 Kymab Ltd Anti-icos Antibodies
SG11202005692WA (en) 2017-12-20 2020-07-29 Harbour Biomed Shanghai Co Ltd Antibodies binding ctla-4 and uses thereof
CN111757757A (zh) 2017-12-21 2020-10-09 梅尔莎纳医疗公司 吡咯并苯并二氮呯抗体共轭物
CN111788227B (zh) 2017-12-27 2025-02-25 百时美施贵宝公司 抗cd40抗体及其用途
SG11202004158QA (en) 2017-12-28 2020-06-29 Nanjing Legend Biotech Co Ltd Single-domain antibodies and variants thereof against tigit
WO2019133847A1 (en) 2017-12-29 2019-07-04 Oncorus, Inc. Oncolytic viral delivery of therapeutic polypeptides
JP7358361B2 (ja) 2018-01-12 2023-10-10 ブリストル－マイヤーズ スクイブ カンパニー Ｔｉｍ３に対する抗体およびその使用
WO2019140150A1 (en) 2018-01-12 2019-07-18 Bristol-Myers Squibb Company Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer
CA3125731A1 (en) 2018-01-12 2019-07-18 KDAc Therapeutics, Inc. Combination of a selective histone deacetylase 3 (hdac3) inhibitor and an immunotherapy agent for the treatment of cancer
CA3084518A1 (en) 2018-01-15 2019-07-18 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against pd-1
KR20200109339A (ko) 2018-01-16 2020-09-22 브리스톨-마이어스 스큅 컴퍼니 Tim3에 대한 항체를 사용하여 암을 치료하는 방법
SG11202006823XA (en) 2018-01-22 2020-08-28 Bristol Myers Squibb Co Compositions and methods of treating cancer
WO2019148445A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same
WO2019160866A2 (en) 2018-02-13 2019-08-22 Checkmate Pharmaceuticals, Inc. Compositions and methods for tumor immunotherapy
CN119792515A (zh) * 2018-02-13 2025-04-11 默沙东有限责任公司 用抗pd-1抗体和抗ctla-4抗体治疗癌症的方法
EP3759125A4 (en) 2018-02-28 2021-12-08 Dana-Farber Cancer Institute, Inc. METHOD OF CANCER TREATMENT USING COMBINATIONS OF ANTI-BTNL2 AND IMMUNCHECKPOINT BLOCKING REAGENTS
WO2019170727A1 (en) 2018-03-06 2019-09-12 Institut Curie Inhibitor of setdb1 histone methyltransferase for use in cancer combination therapy
AU2019236402A1 (en) 2018-03-12 2020-10-01 Assistance Publique-Hôpitaux De Paris (Aphp) Use of caloric restriction mimetics for potentiating chemo-immunotherapy for the treatment of cancers
CN113754768B (zh) 2018-03-14 2023-01-06 表面肿瘤学公司 结合cd39的抗体及其用途
CN110272490B (zh) * 2018-03-14 2021-05-14 上海开拓者生物医药有限公司 靶向ctla-4抗体、其制备方法和用途
CA3094329A1 (en) 2018-03-19 2020-02-20 Multivir Inc. Methods and compositions comprising tumor suppressor gene therapy and cd122/cd132 agonists for the treatment of cancer
SG11202008593PA (en) 2018-03-21 2020-10-29 Five Prime Therapeutics Inc ANTIBODIES BINDING TO VISTA AT ACIDIC pH
JP7351845B2 (ja) 2018-03-23 2023-09-27 ブリストル－マイヤーズ スクイブ カンパニー Ｍｉｃａおよび／またはｍｉｃｂに対する抗体ならびにそれらの使用
CA3094458A1 (en) 2018-03-25 2019-10-31 Snipr Biome Aps. Treating & preventing microbial infections
US10760075B2 (en) 2018-04-30 2020-09-01 Snipr Biome Aps Treating and preventing microbial infections
JP7386174B2 (ja) 2018-03-27 2023-11-24 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Ｈｅｒ２エクソン１９変異を有するがん細胞に対する抗腫瘍活性を有する化合物
CN112313248A (zh) 2018-03-29 2021-02-02 百时美施贵宝公司 纯化单体单克隆抗体的方法
WO2019185792A1 (en) 2018-03-29 2019-10-03 Philogen S.P.A Cancer treatment using immunoconjugates and immune check-point inhibitors
EP3774911A1 (en) 2018-03-30 2021-02-17 Bristol-Myers Squibb Company Methods of treating tumor
WO2019193540A1 (en) 2018-04-06 2019-10-10 Glaxosmithkline Intellectual Property Development Limited Heteroaryl derivatives of formula (i) as atf4 inhibitors
WO2019193541A1 (en) 2018-04-06 2019-10-10 Glaxosmithkline Intellectual Property Development Limited Bicyclic aromatic ring derivatives of formula (i) as atf4 inhibitors
BR112020020479A2 (pt) 2018-04-09 2021-01-12 Checkmate Pharmaceuticals Empacotamento de oligonucleotídeos em partículas similares a vírus
CA3096400A1 (en) 2018-04-09 2019-10-17 Eisai R&D Management Co., Ltd. Certain pladienolide compounds and methods of use
CA3096424A1 (en) 2018-04-12 2019-10-17 Eisai R&D Management Co., Ltd. Pladienolide derivatives as spliceosome targeting agents for treating cancer
WO2019209811A1 (en) 2018-04-24 2019-10-31 Bristol-Myers Squibb Company Macrocyclic toll-like receptor 7 (tlr7) agonists
WO2019209896A1 (en) 2018-04-25 2019-10-31 Innate Tumor Immunity, Inc. Nlrp3 modulators
JP7460608B2 (ja) 2018-05-07 2024-04-02 ジェンマブ エー／エス 抗ｐｄ－１抗体と抗組織因子抗体－薬物コンジュゲートとの組み合わせを用いるがんの治療方法
EA202092136A1 (ru) 2018-05-07 2021-03-22 Генмаб А/С Способы лечения рака с помощью комбинации антитела к pd-1 и конъюгата антитела к тканевому фактору и лекарственного средства
GB201807924D0 (en) 2018-05-16 2018-06-27 Ctxt Pty Ltd Compounds
IL278854B2 (en) 2018-05-23 2026-01-01 Celgene Corp Multiple myeloma treatment and biomarker use for 4-(4-(4-(((2-(6,2-dioxopyridin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl-3-fluorobenzonitrile
PL3796912T3 (pl) 2018-05-23 2023-09-11 Celgene Corporation Związki przeciwproliferacyjne i przeciwciało bispecyficzne przeciwko bcma i cd3 do zastosowania kombinowanego
JP7458997B2 (ja) 2018-05-29 2024-04-01 ブリストル－マイヤーズ スクイブ カンパニー プロドラッグおよび複合体に使用する修飾自己切断部分ならびにその使用方法および製造方法
UY38247A (es) 2018-05-30 2019-12-31 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
WO2019232244A2 (en) 2018-05-31 2019-12-05 Novartis Ag Antibody molecules to cd73 and uses thereof
MX2020012939A (es) 2018-05-31 2021-02-15 Ono Pharmaceutical Co Biomarcadores para determinar la eficacia de los inhibidores de puntos de control inmunitarios.
TW202017569A (zh) 2018-05-31 2020-05-16 美商佩樂敦治療公司 用於抑制cd73之組合物及方法
WO2019232523A1 (en) 2018-06-01 2019-12-05 The Board Of Trustees Of The Leland Stanford Junior University Il-13/il-4 superkines: immune cell targeting constructs and methods of use thereof
IL278740B2 (en) 2018-06-01 2024-01-01 Eisai R&D Man Co Ltd Methods for using splicing modulators
CN119405833A (zh) 2018-06-01 2025-02-11 卫材R&D管理有限公司 剪接调节抗体-药物缀合物及其使用方法
GB201809050D0 (en) 2018-06-01 2018-07-18 E Therapeutics Plc Modulators of tryptophan catabolism
CA3103610A1 (en) 2018-06-12 2019-12-19 The Regents Of The University Of California Single-chain bispecific chimeric antigen receptors for the treatment of cancer
CA3102334A1 (en) 2018-06-15 2019-12-19 Mina Therapeutics Limited Combination therapies comprising c/ebp alpha sarna
JP7097465B2 (ja) 2018-06-19 2022-07-07 アルモ・バイオサイエンシーズ・インコーポレイテッド キメラ抗原受容体細胞療法と併用するｉｌ－１０剤の組成およびその使用方法
JP2021529814A (ja) 2018-07-09 2021-11-04 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 化学化合物
MY201995A (en) 2018-07-09 2024-03-28 Five Prime Therapeutics Inc Antibodies binding to ilt4
CA3176812A1 (en) 2018-07-11 2020-01-16 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
AU2019301120A1 (en) 2018-07-11 2021-02-25 Bristol-Myers Squibb Company Antibodies binding to VISTA at acidic pH
WO2020014583A1 (en) 2018-07-13 2020-01-16 Bristol-Myers Squibb Company Ox-40 agonist, pd-1 pathway inhibitor and ctla-4 inhibitor combination for use in a mehtod of treating a cancer or a solid tumor
WO2020023702A1 (en) 2018-07-25 2020-01-30 AskGene Pharma, Inc. Novel il-21 prodrugs and methods of use thereof
US11554120B2 (en) 2018-08-03 2023-01-17 Bristol-Myers Squibb Company 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor
US12599662B2 (en) 2018-08-06 2026-04-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating cancers
WO2020031107A1 (en) 2018-08-08 2020-02-13 Glaxosmithkline Intellectual Property Development Limited Chemical compounds
WO2020033791A1 (en) 2018-08-09 2020-02-13 Verseau Therapeutics, Inc. Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof
CN113038989A (zh) 2018-08-16 2021-06-25 先天肿瘤免疫公司 咪唑并[4,5-c]喹啉衍生的nlrp3调节剂
SG11202101486RA (en) 2018-08-16 2021-03-30 Innate Tumor Immunity Inc Substitued 4-amino-1h-imidazo[4,5-c]quinoline compounds and improved methods for their preparation
JP7433291B2 (ja) 2018-08-16 2024-02-19 イネイト・テューマー・イミュニティ・インコーポレイテッド イミダゾ［４，５－ｃ］キノリン誘導体のＮＬＲＰ３モジュレーター
EP3617230A1 (en) 2018-09-03 2020-03-04 BioInvent International AB Novel antibodies and nucleotide sequences, and uses thereof
WO2020048942A1 (en) 2018-09-04 2020-03-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for enhancing cytotoxic t lymphocyte-dependent immune responses
WO2020049534A1 (en) 2018-09-07 2020-03-12 Novartis Ag Sting agonist and combination therapy thereof for the treatment of cancer
US20210371537A1 (en) 2018-09-18 2021-12-02 Merrimack Pharmaceuticals, Inc. Anti-tnfr2 antibodies and uses thereof
WO2020058372A1 (en) 2018-09-19 2020-03-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of cancers resistant to immune checkpoint therapy
CN113544144A (zh) 2018-09-19 2021-10-22 高山免疫科学股份有限公司 变体cd80融合蛋白和相关构建体的方法和用途
US20230132385A9 (en) * 2018-09-20 2023-04-27 Tikcro Technologies Ltd. Antibodies specific to ctla-4 and uses thereof
CA3098930A1 (en) 2018-09-21 2020-03-26 Innovent Biologics (Suzhou) Co., Ltd. Novel interleukin-2 and use thereof
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
CN112105634B (zh) 2018-09-21 2024-03-12 信达生物制药(苏州)有限公司 新型白介素2及其用途
CN119306844A (zh) 2018-09-25 2025-01-14 哈普恩治疗公司 Dll3结合蛋白及使用方法
SG11202100935TA (en) 2018-09-28 2021-02-25 Massachusetts Inst Technology Collagen-localized immunomodulatory molecules and methods thereof
US20220040183A1 (en) 2018-10-01 2022-02-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of inhibitors of stress granule formation for targeting the regulation of immune responses
TW202446772A (zh) 2018-10-11 2024-12-01 日商小野藥品工業股份有限公司 Ｓｔｉｎｇ促效化合物
UY38407A (es) 2018-10-15 2020-05-29 Novartis Ag Anticuerpos estabilizadores de trem2
CN112955462B (zh) 2018-10-18 2024-05-07 国家医疗保健研究所 用于治疗实体瘤的βIG-H3拮抗剂和免疫检查点抑制剂的组合
JP2022505647A (ja) 2018-10-23 2022-01-14 ブリストル－マイヤーズ スクイブ カンパニー 腫瘍の処置方法
CA3117050A1 (en) 2018-10-29 2020-05-07 Mersana Therapeutics, Inc. Cysteine engineered antibody-drug conjugates with peptide-containing linkers
TWI844571B (zh) 2018-10-30 2024-06-11 丹麥商珍美寶股份有限公司 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
MX2021005048A (es) 2018-10-31 2021-09-08 Bioatla Inc Anticuerpos anti-ctla4, fragmentos de anticuerpos, sus inmunoconjugados y usos.
US20220001026A1 (en) 2018-11-08 2022-01-06 Modernatx, Inc. Use of mrna encoding ox40l to treat cancer in human patients
CN113330310A (zh) 2018-11-09 2021-08-31 皮埃里亚生物科学有限责任公司 用于测定肿瘤微环境组成的方法和组合物
MX2021005708A (es) 2018-11-16 2021-09-21 Bristol Myers Squibb Co Anticuerpos anti grupo 2a del receptor inhibidor de células asesinas naturales (anti-nkg2a) y usos de los mismos.
EP3880202A2 (en) 2018-11-16 2021-09-22 ArQule, Inc. Pharmaceutical combination for treatment of cancer
CA3119341A1 (en) 2018-11-16 2020-05-22 Neoimmunetech, Inc. Method of treating a tumor with a combination of il-7 protein and an immune checkpoint inhibitor
US20220033848A1 (en) 2018-11-19 2022-02-03 Board Of Regents, The University Of Texas System A modular, polycistronic vector for car and tcr transduction
KR20210116437A (ko) 2018-11-20 2021-09-27 코넬 유니버시티 방사성핵종의 마크로사이클릭 복합체 및 암의 방사선 요법에서의 이의 용도
AU2019384816A1 (en) 2018-11-21 2021-06-24 Board Of Regents, The University Of Texas System Methods and compositions for treating cancer
JP2022511437A (ja) 2018-11-26 2022-01-31 デバイオファーム インターナショナル エス．エー． Ｈｉｖ感染の組み合わせ治療
KR102943054B1 (ko) 2018-11-27 2026-03-23 오노 야꾸힝 고교 가부시키가이샤 면역 체크포인트 저해약 및 폴피리녹스 요법과의 병용에 의한 암 치료
WO2020109355A1 (en) 2018-11-28 2020-06-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and kit for assaying lytic potential of immune effector cells
AU2019386140B2 (en) 2018-11-28 2026-05-28 Board Of Regents, The University Of Texas System Multiplex genome editing of immune cells to enhance functionality and resistance to suppressive environment
JP2022513653A (ja) 2018-11-28 2022-02-09 ブリストル－マイヤーズ スクイブ カンパニー 修飾された重鎖定常領域を含む抗体
EP3886874B1 (en) 2018-11-29 2024-12-11 Board of Regents, The University of Texas System Methods for ex vivo expansion of natural killer cells and use thereof
DK3886914T3 (da) 2018-11-30 2023-07-03 Bristol Myers Squibb Co Antistof omfattende en glutaminholdig letkæde-c-terminal forlængelse, konjugater deraf og fremgangsmåder samt anvendelser
CN113613724B (zh) 2018-11-30 2024-11-08 葛兰素史克知识产权开发有限公司 可用于hiv疗法的化合物
EA202191201A1 (ru) 2018-12-03 2022-01-26 Эдженсис, Инк. Фармацевтические композиции, включающие конъюгаты анти-191p4d12 антитело-лекарственное средство, и способы их применения
WO2020115262A1 (en) 2018-12-07 2020-06-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of cd26 and cd39 as new phenotypic markers for assessing maturation of foxp3+ t cells and uses thereof for diagnostic purposes
CA3117710A1 (en) 2018-12-11 2020-06-18 Theravance Biopharma R&D Ip, Llc Alk5 inhibitors
WO2020123425A2 (en) 2018-12-12 2020-06-18 Bristol-Myers Squibb Company Antibodies modified for transglutaminase conjugation, conjugates thereof, and methods and uses
CN120189526A (zh) 2018-12-13 2025-06-24 卫材R&D管理有限公司 荷伯希二烯抗体-药物缀合物及使用方法
US20220047556A1 (en) 2018-12-17 2022-02-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of sulconazole as a furin inhibitor
BR112021012631A2 (pt) 2018-12-26 2021-12-14 Xilio Dev Inc Anticorpos anti-ctla4 e métodos de uso dos mesmos
MX2021007639A (es) 2018-12-27 2021-08-11 Amgen Inc Formulaciones de virus liofilizadas.
CN114008071B (zh) * 2018-12-27 2025-01-21 吉加根公司 抗ctla-4结合蛋白及其使用方法
CA3124773A1 (en) 2018-12-28 2020-07-02 Transgene M2-defective poxvirus
MX2021008121A (es) 2019-01-03 2021-12-10 Inst Nat Sante Rech Med Metodos y composiciones farmaceuticas para mejorar las respuestas inmunitarias dependientes de celulas t cd8+ en sujetos que sufren de cancer.
EP3908582B1 (en) 2019-01-09 2025-11-12 Celgene Corporation Solid forms comprising (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl) benzyl)piperazin-1-yl)-3-fluorobenzonitrile and salts thereof, and compositions comprising and methods of using the same
AU2020206692B2 (en) 2019-01-09 2025-03-27 Celgene Corporation Pharmaceutical compositions comprising (S)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl) benzyl)piperazin-1-yl)-3-fluorobenzonitrile and methods of using the same
DK3908281T3 (da) 2019-01-09 2024-10-21 Celgene Corp Antiproliferative forbindelser og sekundære aktive midler til anvendelse til behandling af multipelt myelom
CN113301963A (zh) 2019-01-14 2021-08-24 先天肿瘤免疫公司 用于治疗癌症的作为nlrp3调节剂的取代的喹唑啉类
KR102815870B1 (ko) 2019-01-14 2025-05-30 인네이트 튜머 이뮤니티, 인코포레이티드 암의 치료에 사용하기 위한 헤테로시클릭 nlrp3 조정제
CN113286786A (zh) 2019-01-14 2021-08-20 先天肿瘤免疫公司 Nlrp3调节剂
EP3911642B1 (en) 2019-01-14 2026-06-10 Innate Tumor Immunity, Inc. Nlrp3 modulators
CN113508129B (zh) 2019-01-15 2025-02-18 法国国家健康和医学研究院 突变的白介素-34(il-34)多肽及其在治疗中的用途
CN118894938A (zh) 2019-01-22 2024-11-05 百时美施贵宝公司 抗IL-7Rα亚基的抗体及其用途
WO2020154032A1 (en) 2019-01-23 2020-07-30 Massachusetts Institute Of Technology Combination immunotherapy dosing regimen for immune checkpoint blockade
CN113795512A (zh) 2019-02-01 2021-12-14 葛兰素史克知识产权开发有限公司 包含贝兰他单抗莫福汀和抗ox4抗体的癌症组合治疗及其用途和方法
WO2020169472A2 (en) 2019-02-18 2020-08-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of inducing phenotypic changes in macrophages
CN113874083A (zh) 2019-03-01 2021-12-31 梅里麦克制药股份有限公司 抗-tnfr2抗体及其用途
WO2020180864A1 (en) 2019-03-05 2020-09-10 Amgen Inc. Use of oncolytic viruses for the treatment of cancer
MA55316A (fr) 2019-03-13 2022-01-19 Merck Sharp & Dohme Polythérapies anticancéreuses comprenant des agents de blocage de ctla-4 et pd-1
WO2020183011A1 (en) 2019-03-14 2020-09-17 Institut Curie Htr1d inhibitors and uses thereof in the treatment of cancer
WO2020191084A1 (en) 2019-03-18 2020-09-24 The Regents Of The University Of California Augmentation of t-cell activation by oscillatory forces and engineered antigen-presenting cells
US12558351B2 (en) 2019-03-22 2026-02-24 Duke University Compositions and methods for enhancing cancer immune checkpoint therapy
KR20220009941A (ko) 2019-03-26 2022-01-25 더 리젠츠 오브 더 유니버시티 오브 미시간 Stat3의 저분자 분해제
WO2020198676A1 (en) 2019-03-28 2020-10-01 Bristol-Myers Squibb Company Methods of treating tumor
KR20210146348A (ko) 2019-03-28 2021-12-03 브리스톨-마이어스 스큅 컴퍼니 종양을 치료하는 방법
TW202102543A (zh) 2019-03-29 2021-01-16 美商安進公司 溶瘤病毒在癌症新輔助療法中之用途
KR102829207B1 (ko) 2019-03-29 2025-07-02 브리스톨-마이어스 스큅 컴퍼니 크로마토그래피 수지의 소수성을 측정하는 방법
CN119350468A (zh) 2019-03-29 2025-01-24 居里研究所 具有经修饰的生物活性的白介素-2变体
WO2020205467A1 (en) 2019-03-29 2020-10-08 The Regents Of The University Of Michigan Stat3 protein degraders
WO2020201362A2 (en) 2019-04-02 2020-10-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
US20200318200A1 (en) 2019-04-02 2020-10-08 The Brigham And Women's Hospital, Inc. Methods for Identifying Progression of a Primary Melanoma
US20220160692A1 (en) 2019-04-09 2022-05-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of sk2 inhibitors in combination with immune checkpoint blockade therapy for the treatment of cancer
WO2020212484A1 (en) 2019-04-17 2020-10-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treatment of nlrp3 inflammasome mediated il-1beta dependent disorders
JP7720785B2 (ja) 2019-04-18 2025-08-08 ブリストル－マイヤーズ スクイブ カンパニー 低ｐＨで結合するために特異性が増強されたイピリムマブバリアント
EP3966315A1 (en) 2019-05-09 2022-03-16 FUJIFILM Cellular Dynamics, Inc. Methods for the production of hepatocytes
US20220251079A1 (en) 2019-05-16 2022-08-11 Stingthera, Inc. Benzo[b][1,8]naphthyridine acetic acid derivatives and methods of use
JP2022533390A (ja) 2019-05-16 2022-07-22 スティングセラ インコーポレイテッド オキソアクリジニル酢酸誘導体および使用方法
TWI917322B (zh) 2019-05-17 2026-03-11 美商癌症預防製藥股份有限公司 治療家族性腺瘤性瘜肉症之方法
EP3972982A1 (en) 2019-05-20 2022-03-30 Massachusetts Institute of Technology Boronic ester prodrugs and uses thereof
WO2020243329A1 (en) 2019-05-28 2020-12-03 The Regents Of The University Of California Methods for treating small cell neuroendocrine and related cancers
US20220363760A1 (en) 2019-05-30 2022-11-17 Bristol-Myers Squibb Company Multi-tumor gene signature for suitability to immuno-oncology therapy
JP2022534982A (ja) 2019-05-30 2022-08-04 ブリストル－マイヤーズ スクイブ カンパニー 細胞局在化シグネチャーおよびその使用
WO2020243570A1 (en) 2019-05-30 2020-12-03 Bristol-Myers Squibb Company Cell localization signature and combination therapy
CN114173822B (zh) 2019-06-03 2025-01-10 芝加哥大学 用胶原结合药物载体治疗癌症的方法和组合物
CN114206355A (zh) 2019-06-03 2022-03-18 芝加哥大学 用靶向癌症的佐剂治疗癌症的方法和组合物
US11246906B2 (en) 2019-06-11 2022-02-15 Alkermes Pharma Ireland Limited Compositions and methods for subcutaneous administration of cancer immunotherapy
CN114341189A (zh) 2019-06-12 2022-04-12 奥美药业有限公司 全新il-15前药及其应用
WO2020252336A1 (en) 2019-06-12 2020-12-17 Vanderbilt University Dibenzylamines as amino acid transport inhibitors
US20220304984A1 (en) 2019-06-12 2022-09-29 Vanderbilt University Amino acid transport inhibitors and the uses thereof
CA3143211A1 (en) 2019-06-26 2020-12-30 Glaxosmithkline Intellectual Property Development Limited Il1rap binding proteins
JP2022538974A (ja) 2019-06-26 2022-09-07 マサチューセッツ インスチテュート オブ テクノロジー 免疫調節融合タンパク質－金属水酸化物錯体およびその方法
CN115443329A (zh) 2019-06-27 2022-12-06 乔治华盛顿大学国会特许非营利公司 Hdac6激活的巨噬细胞、其组合物及用途
BR112021026832A2 (pt) 2019-07-02 2022-05-10 Hutchinson Fred Cancer Res Vetores ad35 recombinantes e aprimoramentos da terapia gênica relacionada
CN114174336B (zh) * 2019-07-15 2024-10-11 英特维特国际股份有限公司 针对人和犬ctla-4的犬源化抗体
AU2020315401B2 (en) 2019-07-16 2025-05-22 The Regents Of The University Of Michigan Imidazopyrimidines as EED inhibitors and the use thereof
GB201910304D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
GB201910305D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
BR112021005478A2 (pt) 2019-07-24 2021-06-15 H. Lundbeck A/S anticorpos anti-mglur5 e uso dos mesmos
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
EP3778875A1 (en) 2019-08-14 2021-02-17 MaxiVax SA Immortalized myoblast cell lines and uses thereof
US11851490B2 (en) 2019-08-15 2023-12-26 Northwestern University Methods and compositions for treating, inhibiting, and/or preventing heterotopic ossification
GB201912107D0 (en) 2019-08-22 2019-10-09 Amazentis Sa Combination
AU2020336381A1 (en) 2019-08-27 2022-03-03 The Regents Of The University Of Michigan Cereblon E3 ligase inhibitors
EP4021581A4 (en) 2019-08-30 2023-08-30 Foundation Medicine, Inc. Kmt2a-maml2 fusion molecules and uses thereof
WO2021043961A1 (en) 2019-09-06 2021-03-11 Glaxosmithkline Intellectual Property Development Limited Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and chemotherapy
WO2021046293A1 (en) 2019-09-06 2021-03-11 Glaxosmithkline Intellectual Property Development Limited Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and tremelimumab
KR20220062500A (ko) 2019-09-16 2022-05-17 서피스 온콜로지, 인크. 항-cd39 항체 조성물 및 방법
US20240377413A1 (en) 2019-09-16 2024-11-14 Bristol-Myers Squibb Company Dual capture method for analysis of antibody-drug conjugates
CA3151022A1 (en) 2019-09-17 2021-03-25 Bial - R&D Investments, S.A. Substituted n-heterocyclic carboxamides as acid ceramidase inhibitors and their use as medicaments
CA3150700A1 (en) 2019-09-17 2021-03-25 Renato T. Skerlj IMIDAZOLE SUBSTITUTE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
CN114901652A (zh) 2019-09-17 2022-08-12 比亚尔R&D投资股份公司 用于治疗医学病症的经取代的饱和和不饱和n-杂环甲酰胺及相关化合物
JP2022548881A (ja) 2019-09-18 2022-11-22 ノバルティス アーゲー Ｅｎｔｐｄ２抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
TW202124446A (zh) 2019-09-18 2021-07-01 瑞士商諾華公司 與ｅｎｔｐｄ２抗體之組合療法
AU2020348849A1 (en) 2019-09-19 2022-04-07 The Regents Of The University Of Michigan Spirocyclic androgen receptor protein degraders
CA3149719A1 (en) 2019-09-19 2021-03-25 Bristol-Myers Squibb Company Antibodies binding to vista at acidic ph
WO2021055994A1 (en) 2019-09-22 2021-03-25 Bristol-Myers Squibb Company Quantitative spatial profiling for lag-3 antagonist therapy
US20220347294A1 (en) 2019-09-23 2022-11-03 The Regents Of The University Of Michigan Compositions and methods for increasing the efficacy of immunotherapies and vaccines
TWI764291B (zh) 2019-09-24 2022-05-11 財團法人工業技術研究院 抗tigit抗體及使用方法
CA3151078A1 (en) 2019-09-25 2021-04-01 Surface Oncology, Inc. Anti-il-27 antibodies and uses thereof
EP3800201A1 (en) 2019-10-01 2021-04-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Cd28h stimulation enhances nk cell killing activities
US20220363776A1 (en) 2019-10-04 2022-11-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of ovarian cancer, breast cancer or pancreatic cancer
US20220401539A1 (en) 2019-10-22 2022-12-22 Institut Curie Immunotherapy Targeting Tumor Neoantigenic Peptides
US11459389B2 (en) 2019-10-24 2022-10-04 Massachusetts Institute Of Technology Monoclonal antibodies that bind human CD161
CN114630679A (zh) 2019-10-25 2022-06-14 第一三共株式会社 抗garp抗体和免疫调节剂的组合
NL2024108B1 (en) 2019-10-26 2021-07-19 Vitroscan B V Methods and apparatus for measuring immune-cell mediated anti-tumoroid responses
NL2024107B1 (en) 2019-10-26 2021-07-19 Vitroscan B V Compositions for Patient Specific Immunotherapy
US12514927B2 (en) 2019-10-30 2026-01-06 Duke University Immunotherapy with combination therapy comprising an immunotoxin
WO2021087458A2 (en) 2019-11-02 2021-05-06 Board Of Regents, The University Of Texas System Targeting nonsense-mediated decay to activate p53 pathway for the treatment of cancer
CA3160151A1 (en) 2019-11-04 2021-05-14 Seagen Inc. Anti-cd30 antibody-drug conjugates and their use for the treatment of hiv infection
CA3157196A1 (en) 2019-11-05 2021-05-14 Celgene Corporation Combination therapy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl)-2,2-difluoroacetamide
WO2021092220A1 (en) 2019-11-06 2021-05-14 Bristol-Myers Squibb Company Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
WO2021092221A1 (en) 2019-11-06 2021-05-14 Bristol-Myers Squibb Company Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
TW202131954A (zh) 2019-11-07 2021-09-01 丹麥商珍美寶股份有限公司 利用鉑類劑與抗組織因子抗體－藥物共軛體之組合來治療癌症之方法
WO2021090272A1 (en) 2019-11-07 2021-05-14 Genmab A/S Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
EP4054723A1 (en) 2019-11-08 2022-09-14 Bristol-Myers Squibb Company Lag-3 antagonist therapy for melanoma
US20220396839A1 (en) 2019-11-12 2022-12-15 Foundation Medicine, Inc. Methods of detecting a fusion gene encoding a neoantigen
EP4058150A2 (en) * 2019-11-15 2022-09-21 Genzyme Corporation Biparatopic cd73 antibodies
KR20220104208A (ko) 2019-11-22 2022-07-26 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 Alk5 억제제로서 치환된 1,5-나프티리딘 또는 퀴놀린
EP3824954A1 (en) 2019-11-22 2021-05-26 Centre National de la Recherche Scientifique Device, apparatus and method for minibeam radiation therapy
TW202128155A (zh) 2019-11-27 2021-08-01 日商賽多利克公司 醫藥組成物
WO2021113644A1 (en) 2019-12-05 2021-06-10 Multivir Inc. Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
CN115916818A (zh) 2019-12-11 2023-04-04 库利南肿瘤股份有限公司 抗cd19抗体和多特异性结合蛋白
WO2021119753A1 (en) 2019-12-18 2021-06-24 Ctxt Pty Limited Compounds
WO2021127554A1 (en) 2019-12-19 2021-06-24 Bristol-Myers Squibb Company Combinations of dgk inhibitors and checkpoint antagonists
MY202559A (en) 2019-12-27 2024-05-08 Chugai Pharmaceutical Co Ltd Anti-ctla-4 antibody and use thereof
MX2022008412A (es) 2020-01-07 2022-08-08 Univ Texas Variantes de enzima que agotan metiltioadenosina/adenosina mejorada humana para terapia de cancer.
WO2021142203A1 (en) 2020-01-10 2021-07-15 Innate Tumor Immunity, Inc. Nlrp3 modulators
AU2021205981A1 (en) 2020-01-11 2022-07-14 AskGene Pharma, Inc. Novel masked cytokines and methods of use thereof
AU2021209045A1 (en) 2020-01-13 2022-07-28 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack
WO2021146749A1 (en) 2020-01-13 2021-07-22 The University Of Chicago Toll-like receptor agonist formulations and methods of use
CN115362168A (zh) 2020-01-14 2022-11-18 辛德凯因股份有限公司 偏向化il2突变蛋白方法和组合物
EP4096718A1 (en) 2020-01-28 2022-12-07 GlaxoSmithKline Intellectual Property Development Limited Combination treatments and uses and methods thereof
KR20220133238A (ko) 2020-01-29 2022-10-04 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 Nrg1 융합체가 있는 암의 치료를 위한 포지오티닙의 용도
KR20220132555A (ko) 2020-01-29 2022-09-30 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 Nrg1 융합체를 사용한 암 치료를 위한 egfr/her2 티로신 키나제 억제제 및/또는 her2/her3 항체의 사용
WO2021158938A1 (en) 2020-02-06 2021-08-12 Bristol-Myers Squibb Company Il-10 and uses thereof
WO2021167908A1 (en) 2020-02-17 2021-08-26 Board Of Regents, The University Of Texas System Methods for expansion of tumor infiltrating lymphocytes and use thereof
JP2023517011A (ja) 2020-03-05 2023-04-21 ネオティーエックス セラピューティクス リミテッド 免疫細胞を用いて癌を治療するための方法および組成物
US20230140384A1 (en) 2020-03-09 2023-05-04 Bristol-Myers Squibb Company Antibodies to cd40 with enhanced agonist activity
US20230093147A1 (en) 2020-03-09 2023-03-23 President And Fellows Of Harvard College Methods and compositions relating to improved combination therapies
EP3878446A1 (en) 2020-03-09 2021-09-15 Universite De Geneve Hsd11b1 inhibitors for use in immunotherapy and uses thereof
US12522623B2 (en) 2020-03-26 2026-01-13 Regents Of The University Of Michigan Small molecule STAT protein degraders
US12091681B2 (en) 2020-03-27 2024-09-17 Mendus B.V. Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
TW202204339A (zh) 2020-03-31 2022-02-01 美商施萬生物製藥研發 Ip有限責任公司 經取代的嘧啶及使用方法
US20230151024A1 (en) 2020-04-10 2023-05-18 Ono Pharmaceutical Co., Ltd. Sting agonistic compound
US20230141284A1 (en) 2020-04-10 2023-05-11 Ono Pharmaceutical Co., Ltd. Cancer therapeutic method
CA3175523A1 (en) 2020-04-13 2021-10-21 Antti Virtanen Methods, complexes and kits for detecting or determining an amount of a .beta.-coronavirus antibody in a sample
US20230149560A1 (en) 2020-04-20 2023-05-18 Massachusetts Institute Of Technology Lipid compositions for delivery of sting agonist compounds and uses thereof
WO2021216670A1 (en) 2020-04-21 2021-10-28 University Of Rochester Inhibitors of human epididymus protein 4
EP4139440B1 (en) 2020-04-22 2026-08-19 Iovance Biotherapeutics, Inc. Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
US20230242647A1 (en) 2020-05-01 2023-08-03 Novartis Ag Engineered immunoglobulins
WO2021220218A1 (en) 2020-05-01 2021-11-04 Novartis Ag Immunoglobulin variants
WO2021224186A1 (en) 2020-05-04 2021-11-11 Institut Curie New pyridine derivatives as radiosensitizers
EP4149512A4 (en) 2020-05-12 2024-06-05 Board of Regents, The University of Texas System Methods for treating glioblastoma
EP4149547A4 (en) 2020-05-13 2024-08-14 Adagene AG Compositions and methods for treating cancer
AU2021273014A1 (en) 2020-05-13 2022-11-17 AbbVie Deutschland GmbH & Co. KG Anti-hemojuvelin (HJV) antibodies for treating anemia of chronic disease
ES3075793T3 (en) 2020-05-13 2026-08-07 Disc Medicine Inc Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
US20230192867A1 (en) 2020-05-15 2023-06-22 Bristol-Myers Squibb Company Antibodies to garp
AU2021275489A1 (en) 2020-05-20 2022-12-01 Centre National De La Recherche Scientifique - Cnrs - Single domain antibodies and their use in cancer therapies
CN115803084A (zh) 2020-05-21 2023-03-14 得克萨斯大学体系董事会 具有vgll1特异性的t细胞受体和其用途
WO2021238932A1 (zh) * 2020-05-26 2021-12-02 百奥泰生物制药股份有限公司 多特异性抗体及其应用
EP4157319A1 (en) 2020-05-28 2023-04-05 Modernatx, Inc. Use of mrnas encoding ox40l, il-23 and il-36gamma for treating cancer
CA3180060A1 (en) 2020-05-29 2021-12-02 Zongmin ZHAO Living cells engineered with polyphenol-functionalized biologically active nanocomplexes
WO2021245071A1 (en) 2020-06-03 2021-12-09 Mv Biotherapeutics Sa Combination of an atp-hydrolyzing enzyme and an immune checkpoint modulator and uses thereof
WO2021247836A1 (en) 2020-06-03 2021-12-09 Board Of Regents, The University Of Texas System Methods for targeting shp-2 to overcome resistance
CN116323607A (zh) 2020-06-10 2023-06-23 施万生物制药研发Ip有限责任公司 用作alk5抑制剂的萘啶衍生物
US20230293530A1 (en) 2020-06-24 2023-09-21 Yeda Research And Development Co. Ltd. Agents for sensitizing solid tumors to treatment
CN115916191B (zh) 2020-06-25 2026-06-23 新基公司 用组合疗法治疗癌症的方法
KR20230028492A (ko) 2020-06-29 2023-02-28 젠맵 에이/에스 항-조직 인자 항체-약물 접합체 및 암의 치료에서의 그의 용도
EP4172621A1 (en) 2020-06-30 2023-05-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapies
WO2022003568A1 (en) 2020-06-30 2022-01-06 Dcprime B.V. Use of leukemia-derived cells in ovarian cancer vaccines
JP7741831B2 (ja) 2020-06-30 2025-09-18 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 術前補助療法及び根治手術後の固形がんを患っている患者の再発及び／又は死亡のリスクを予測するための方法
WO2022003156A1 (en) 2020-07-02 2022-01-06 Oncurious Nv Ccr8 non-blocking binders
ES2988714T3 (es) 2020-07-07 2024-11-21 Celgene Corp Composiciones farmacéuticas que comprenden (S)-4-(4-(4-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-4-il)oxi)metil)bencilo)piperazin-1-il)-3-fluorobenzonitrilo y métodos de uso de las mismas
KR102594083B1 (ko) 2020-07-07 2023-10-25 칸큐어 엘엘씨 Mic 항체 및 결합제 및 이의 사용 방법
CN116234568A (zh) 2020-07-07 2023-06-06 生物技术公司 用于hpv阳性癌症的治疗性rna
WO2022011204A1 (en) 2020-07-10 2022-01-13 The Regents Of The University Of Michigan Small molecule androgen receptor protein degraders
WO2022011205A1 (en) 2020-07-10 2022-01-13 The Regents Of The University Of Michigan Androgen receptor protein degraders
US12655219B2 (en) 2020-07-21 2026-06-16 Shanghai Junshi Biosciences Co., Ltd. Anti-CTLA-4 antibody and use thereof
EP4185568A1 (en) 2020-07-24 2023-05-31 The University of Rochester Inhibitors of interleukin-1 receptor-associated kinases 1 and 4
WO2022029494A1 (en) 2020-08-04 2022-02-10 Abbott Rapid Diagnostics International Unlimited Company Assays for detecting sars-cov-2
US20220043000A1 (en) 2020-08-04 2022-02-10 Abbott Laboratories Methods and kits for detecting sars-cov-2 protein in a sample
JP2023534765A (ja) 2020-08-07 2023-08-10 フォーティス セラピューティクス，インク． 免疫複合体を標的とするｃｄ４６およびその使用方法
MX2023002332A (es) 2020-08-28 2023-03-21 Bristol Myers Squibb Co Terapia con antagonistas del gen 3 de activacion de linfocitos (lag-3) para carcinoma hepatocelular.
IL300916A (en) 2020-08-31 2023-04-01 Bristol Myers Squibb Co Cell localization signature and immunotherapy
US12577621B2 (en) 2020-09-08 2026-03-17 Duke University LRRK2 mutations as biomarkers for the prediction of immune checkpoint response in cancer
WO2022072820A1 (en) 2020-10-02 2022-04-07 Dracen Pharmaceuticals, Inc. Lyophilized composition comprising (s)-isopropyl 2-((s)-2- acetamido-3-(1h-indol-3-yl)propanamido)-6-diazo-5- oxohexanoate for subcutaneous administration and the use thereof
CA3195019A1 (en) 2020-10-06 2022-04-14 Maria Fardis Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
WO2022079270A1 (en) 2020-10-16 2022-04-21 Université D'aix-Marseille Anti-gpc4 single domain antibodies
EP4232453A1 (en) 2020-10-20 2023-08-30 Institut Curie Metallic trans-(n-heterocyclic carbene)-amine-platinum complexes and uses thereof for treating cancer
CA3196496A1 (en) 2020-10-23 2022-04-28 Laurence David TOMS Lag-3 antagonist therapy for lung cancer
CN116744969A (zh) 2020-11-04 2023-09-12 海德堡医药研究有限责任公司 用于癌症疗法的包含免疫检查点抑制剂与抗体-鹅膏毒素缀合物的组合的组合物
CA3200661A1 (en) 2020-11-05 2022-05-12 Board Of Regents, The University Of Texas System Engineered t cell receptors targeting egfr antigens and methods of use
WO2022097065A2 (en) 2020-11-06 2022-05-12 Novartis Ag ANTIBODY Fc VARIANTS
TW202233248A (zh) 2020-11-08 2022-09-01 美商西健公司 組合療法
CA3201499A1 (en) 2020-11-13 2022-05-19 Catamaran Bio, Inc. Genetically modified natural killer cells and methods of use thereof
JP7816164B2 (ja) 2020-11-13 2026-02-18 小野薬品工業株式会社 Ｅｐ４拮抗薬と免疫チェックポイント阻害物質との併用によるがん治療
MX2023005528A (es) 2020-11-17 2023-06-23 Seagen Inc Metodos de tratamiento del cancer con una combinacion de tucatinib y un anticuerpo anti-pd-1/anti-pd-l1.
EP4247352A1 (en) 2020-11-18 2023-09-27 Institut Curie Dimers of biguanidines and their therapeutic uses
JP2023550419A (ja) * 2020-11-18 2023-12-01 スーチョウ・トランスセンタ・セラピューティクス・カンパニー・リミテッド 二機能性分子
EP4251645A1 (en) 2020-11-25 2023-10-04 Catamaran Bio, Inc. Cellular therapeutics engineered with signal modulators and methods of use thereof
WO2022119841A1 (en) 2020-12-01 2022-06-09 Abbott Laboratories Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
WO2023102384A1 (en) 2021-11-30 2023-06-08 Abbott Laboratories Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
PH12023500013A1 (en) 2020-12-04 2024-03-11 Tidal Therapeutics Inc Ionizable cationic lipids and lipi nanoparticles, and methods of synthesis and use thereof
EP4259661A1 (en) 2020-12-14 2023-10-18 Novartis AG Reversal binding agents for anti-natriuretic peptide receptor 1 (npr1) antibodies and uses thereof
WO2022130206A1 (en) 2020-12-16 2022-06-23 Pfizer Inc. TGFβr1 INHIBITOR COMBINATION THERAPIES
JP2023554395A (ja) 2020-12-17 2023-12-27 アイオバンス バイオセラピューティクス，インコーポレイテッド Ｃｔｌａ－４及びｐｄ－１阻害剤と併用した腫瘍浸潤リンパ球療法による治療
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
WO2022136649A1 (en) 2020-12-24 2022-06-30 Oncurious Nv Non-blocking human ccr8 binders
CA3206125A1 (en) 2020-12-24 2022-06-30 Vib Vzw Murine cross-reactive human ccr8 binders
EP4267617A1 (en) 2020-12-24 2023-11-01 Vib Vzw Human ccr8 binders
AU2021416156A1 (en) 2020-12-28 2023-06-22 Bristol-Myers Squibb Company Methods of treating tumors
PT4267105T (pt) 2020-12-28 2025-04-30 Bristol Myers Squibb Co Composições de anticorpos e métodos de utilização das mesmas
WO2022147147A1 (en) 2020-12-30 2022-07-07 Abbott Laboratories Methods for determining sars-cov-2 antigen and anti-sars-cov-2 antibody in a sample
US20250163162A1 (en) 2021-01-11 2025-05-22 Synthekine, Inc. Compositions and methods related to receptor pairing
EP4277934A1 (en) 2021-01-14 2023-11-22 Institut Curie Her2 single domain antibodies variants and cars thereof
JP2024503480A (ja) 2021-01-19 2024-01-25 ウィリアム マーシュ ライス ユニバーシティ ポリペプチドの骨特異的送達法
CA3208974A1 (en) * 2021-01-20 2022-07-28 Bioentre Llc Ctla4-binding proteins and methods of treating cancer
KR20230135075A (ko) 2021-01-22 2023-09-22 멘두스 비.브이. 종양 백신접종 방법
CA3206549A1 (en) 2021-01-29 2022-08-04 Frederick G. Vogt Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy
EP4284950A4 (en) 2021-01-29 2024-12-25 Board of Regents, The University of Texas System METHODS OF TREATMENT OF CANCER USING KINASE INHIBITORS
WO2022187419A1 (en) 2021-03-03 2022-09-09 The Regents Of The University Of Michigan Small molecule degraders of androgen receptor
WO2022187423A1 (en) 2021-03-03 2022-09-09 The Regents Of The University Of Michigan Cereblon ligands
WO2022190058A1 (en) 2021-03-12 2022-09-15 Dcprime B.V. Methods of vaccination and use of cd47 blockade
WO2022189618A1 (en) 2021-03-12 2022-09-15 Institut Curie Nitrogen-containing heterocycles as radiosensitizers
EP4314253A2 (en) 2021-03-25 2024-02-07 Iovance Biotherapeutics, Inc. Methods and compositions for t-cell coculture potency assays and use with cell therapy products
JP2024514530A (ja) 2021-04-02 2024-04-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 切断型ｃｄｃｐ１に対する抗体およびその使用
EP4319755A4 (en) 2021-04-08 2025-03-26 Board of Regents, The University of Texas System Compounds and methods for theranostic targeting of parp activity
EP4070799A1 (en) 2021-04-08 2022-10-12 Nuvamid SA Compositions for the improvement of sport performance
WO2022217022A1 (en) 2021-04-10 2022-10-13 Profoundbio Us Co. Folr1 binding agents, conjugates thereof and methods of using the same
EP4079310A1 (en) 2021-04-20 2022-10-26 Nuvamid SA Nmn and derivatives for its use in the treatment of alpha-synucleinopathies
EP4079311B1 (en) 2021-04-20 2025-10-01 Nuvamid SA Nmn and derivatives for use in the treatment of depression and/or anxiety in patients having a form of parkinsonism
CA3216459A1 (en) 2021-04-23 2022-10-27 Profoundbio Us Co. Anti-cd70 antibodies, conjugates thereof and methods of using the same
EP4329734A4 (en) 2021-04-26 2025-04-02 Celanese EVA Performance Polymers LLC Implantable device for the delayed release of a macromolecular drug compound
WO2022229644A1 (en) 2021-04-28 2022-11-03 Mina Therapeutics Limited Combination therapies comprising c/ebp alpha sarna
US20240269282A1 (en) 2021-05-10 2024-08-15 Institut Curie Methods for the Treatment of Cancer, Inflammatory Diseases and Autoimmune Diseases
AU2022279156A1 (en) 2021-05-18 2023-11-02 Abbott Laboratories Methods of evaluating brain injury in a pediatric subject
WO2022251359A1 (en) 2021-05-26 2022-12-01 Theravance Biopharma R&D Ip, Llc Bicyclic inhibitors of alk5 and methods of use
US20240277842A1 (en) 2021-06-07 2024-08-22 Providence Health & Services - Oregon Cxcr5, pd-1, and icos expressing tumor reactive cd4 t cells and their use
EP4353265A4 (en) 2021-06-10 2024-10-02 ONO Pharmaceutical Co., Ltd. METHOD OF TREATING CANCER BY MEANS OF A COMBINATION OF A CD47 INHIBITOR, AN IMMUNE CHECKPOINT INHIBITOR AND STANDARD THERAPY
WO2022266034A1 (en) 2021-06-14 2022-12-22 Abbott Laboratories Methods of diagnosing or aiding in diagnosis of brain injury caused by acoustic energy, electromagnetic energy, an over pressurization wave, and/or blast wind
CN117616123B (zh) 2021-06-25 2024-11-08 中外制药株式会社 抗ctla-4抗体
US12448451B2 (en) 2021-06-25 2025-10-21 Chugai Seiyaku Kabushiki Kaisha Anti-CTLA-4 antibody and use thereof
IL308633B2 (en) 2021-06-25 2025-12-01 Chugai Pharmaceutical Co Ltd Use of anti-ctla-4 antibody
US20240316005A1 (en) 2021-07-05 2024-09-26 Institut National de la Santé et de la Recherche Médicale Gene signatures for predicting survival time in patients suffering from renal cell carcinoma
WO2023285552A1 (en) 2021-07-13 2023-01-19 BioNTech SE Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
EP4370139A4 (en) 2021-07-14 2025-10-15 Synthekine Inc METHODS AND COMPOSITIONS FOR USE IN CELL THERAPY FOR NEOPLASTIC DISEASE
JP2024531910A (ja) 2021-08-04 2024-09-03 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイト Ｌａｔ活性化キメラ抗原受容体ｔ細胞及びその使用方法
EP4380682A1 (en) 2021-08-05 2024-06-12 Institut Curie Scanning dynamic device for minibeams production
MX2024001877A (es) 2021-08-10 2024-02-28 Kymab Ltd Tratamiento de dermatitis atopica.
JP2024534265A (ja) 2021-08-23 2024-09-18 イミュニタス セラピューティクス，インコーポレーテッド 抗ｃｄ１６１抗体及びその使用
CA3230038A1 (en) 2021-08-31 2023-03-09 Hongwei Zhang Methods and systems of diagnosing brain injury
CN118715440A (zh) 2021-08-31 2024-09-27 雅培实验室 诊断脑损伤的方法和系统
US20240316061A1 (en) 2021-09-17 2024-09-26 Institut Curie Bet inhibitors for treating pab1 deficient cancer
US20250084155A1 (en) 2021-09-29 2025-03-13 Board Of Regents, The University Of Texas System Anti-hsp70 antibodies and therapeutic uses thereof
WO2023056268A1 (en) 2021-09-30 2023-04-06 Abbott Laboratories Methods and systems of diagnosing brain injury
AU2022361488A1 (en) 2021-10-05 2024-05-02 Cytovia Therapeutics, Llc Natural killer cells and methods of use thereof
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
IL312221A (en) 2021-10-20 2024-06-01 Synthekine Inc Heterodimeric fc cytokines and uses thereof
AU2022372894A1 (en) 2021-10-20 2024-04-18 Takeda Pharmaceutical Company Limited Compositions targeting bcma and methods of use thereof
US20240409934A1 (en) 2021-10-25 2024-12-12 Board Of Regents, The University Of Texas System Foxo1-targeted therapy for the treatment of cancer
EP4423249A1 (en) 2021-10-28 2024-09-04 Lyell Immunopharma, Inc. Methods for culturing immune cells
CN118451108A (zh) 2021-10-29 2024-08-06 思进公司 用抗pd-1抗体和抗cd30抗体-药物缀合物的组合治疗癌症的方法
WO2023077090A1 (en) 2021-10-29 2023-05-04 Bristol-Myers Squibb Company Lag-3 antagonist therapy for hematological cancer
CN113907045B (zh) * 2021-11-09 2023-01-06 派生特（福州）生物科技有限公司 一种新品系猪的培育方法及其应用
WO2023089032A1 (en) 2021-11-19 2023-05-25 Institut Curie Methods for the treatment of hrd cancer and brca-associated cancer
EP4433096A1 (en) 2021-11-19 2024-09-25 Ardeagen Corporation Gpc3 binding agents, conjugates thereof and methods of using the same
WO2023097024A1 (en) * 2021-11-24 2023-06-01 Dana-Farber Cancer Institute, Inc. Antibodies against ctla-4 and methods of use thereof
WO2023099763A1 (en) 2021-12-03 2023-06-08 Institut Curie Sirt6 inhibitors for use in treating resistant hrd cancer
JP2025503439A (ja) 2021-12-17 2025-02-04 アボット・ラボラトリーズ 血液試料におけるｕｃｈ－ｌ１、ｇｆａｐ及び他のバイオマーカーを決定するためのシステム及び方法
CN119836296A (zh) 2021-12-30 2025-04-15 新免疫技术有限公司 用il-7蛋白和vegf拮抗剂的组合治疗肿瘤的方法
AU2023213937A1 (en) 2022-01-26 2024-07-18 Bristol-Myers Squibb Company Combination therapy for hepatocellular carcinoma
EP4469065A1 (en) 2022-01-28 2024-12-04 Iovance Biotherapeutics, Inc. Cytokine associated tumor infiltrating lymphocytes compositions and methods
CN118541390A (zh) * 2022-01-30 2024-08-23 百奥赛图(北京)医药科技股份有限公司 抗ctla4/ox40双特异性抗体及其用途
JP2025507303A (ja) 2022-02-04 2025-03-18 アボット・ラボラトリーズ 試料におけるユビキチンカルボキシ末端ヒドロラーゼｌ１及び／又はグリア原線維性酸性タンパク質の存在を検出する又はその量を測定するためのラテラルフロー方法、アッセイ及びデバイス
WO2023154799A1 (en) 2022-02-14 2023-08-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Combination immunotherapy for treating cancer
US20230277669A1 (en) 2022-02-24 2023-09-07 Amazentis Sa Uses of urolithins
KR20240153583A (ko) 2022-02-25 2024-10-23 브리스톨-마이어스 스큅 컴퍼니 결장직장암종에 대한 병용 요법
WO2023168404A1 (en) 2022-03-04 2023-09-07 Bristol-Myers Squibb Company Methods of treating a tumor
CN119156403A (zh) 2022-03-08 2024-12-17 阿伦蒂斯治疗股份公司 抗紧密连接蛋白-1抗体增加t细胞可用性的用途
CA3259975A1 (en) 2022-03-15 2023-09-21 Compugen Ltd. Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer
WO2023176881A1 (ja) 2022-03-16 2023-09-21 第一三共株式会社 多重特異的分子と免疫チェックポイント阻害剤の組み合わせ
US20250206775A1 (en) 2022-03-18 2025-06-26 Bristol-Myers Squibb Company Methods of isolating polypeptides
CN119816320A (zh) 2022-03-24 2025-04-11 居里研究所 靶向胶质母细胞瘤中肿瘤转座元件衍生的新抗原肽的免疫疗法
EP4499677A1 (en) 2022-03-31 2025-02-05 Institut Curie Modified rela protein for inducing interferon expression and engineered immune cells with improved interferon expression
WO2023196987A1 (en) 2022-04-07 2023-10-12 Bristol-Myers Squibb Company Methods of treating tumor
WO2023196988A1 (en) 2022-04-07 2023-10-12 Modernatx, Inc. Methods of use of mrnas encoding il-12
US20250222106A1 (en) 2022-04-07 2025-07-10 Institut Curie Myeloid cells modified by chimeric antigen receptor with cd40 and uses thereof for anti-cancer therapy
EP4504245A1 (en) 2022-04-07 2025-02-12 Institut Curie Myeloid cells modified by chimeric antigen receptor and uses thereof for anti-cancer therapy
EP4507704A1 (en) 2022-04-15 2025-02-19 Iovance Biotherapeutics, Inc. Til expansion processes using specific cytokine combinations and/or akti treatment
IL316174A (en) 2022-04-26 2024-12-01 Novartis Ag Multiple specific antibodies targeting IL-13 and IL-18
WO2023211972A1 (en) 2022-04-28 2023-11-02 Medical University Of South Carolina Chimeric antigen receptor modified regulatory t cells for treating cancer
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
WO2023213763A1 (en) 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
JP2025515166A (ja) 2022-05-06 2025-05-13 ジェンマブ エー／エス 抗組織因子抗体－薬物コンジュゲートを用いたがんの治療方法
CN119255825A (zh) 2022-05-24 2025-01-03 第一三共株式会社 抗-cdh6抗体-药物缀合物的剂量方案
AR129423A1 (es) 2022-05-27 2024-08-21 Viiv Healthcare Co Compuestos útiles en la terapia contra el hiv
AU2023281061A1 (en) 2022-06-02 2024-12-05 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
AR129560A1 (es) 2022-06-08 2024-09-04 Tidal Therapeutics Inc Lípidos catiónicos ionizables y nanopartículas lipídicas, y métodos de síntesis y uso de los mismos
US20260053913A1 (en) 2022-06-10 2026-02-26 Bioentre Llc Combinations of ctla4 binding proteins and methods of treating cancer
WO2024006876A1 (en) 2022-06-29 2024-01-04 Abbott Laboratories Magnetic point-of-care systems and assays for determining gfap in biological samples
GB202209518D0 (en) 2022-06-29 2022-08-10 Snipr Biome Aps Treating & preventing E coli infections
CN119654339A (zh) 2022-07-01 2025-03-18 特兰斯吉恩股份有限公司 包含表面活性蛋白-d和tnfsf成员的融合蛋白
JP2025524992A (ja) 2022-07-28 2025-08-01 アストラゼネカ ユーケー リミテッド 抗体－薬物コンジュゲートと二重特異性チェックポイント阻害剤との組み合わせ
WO2024028794A1 (en) 2022-08-02 2024-02-08 Temple Therapeutics BV Methods for treating endometrial and ovarian hyperproliferative disorders
WO2024040175A1 (en) 2022-08-18 2024-02-22 Pulmatrix Operating Company, Inc. Methods for treating cancer using inhaled angiogenesis inhibitor
WO2024043227A1 (ja) 2022-08-23 2024-02-29 小野薬品工業株式会社 二重特異性抗体
WO2024046389A1 (zh) * 2022-08-31 2024-03-07 百奥泰生物制药股份有限公司 抗tigit抗体和抗ctla-4抗体联合用于治疗肿瘤中的应用
WO2024052356A1 (en) 2022-09-06 2024-03-14 Institut National de la Santé et de la Recherche Médicale Inhibitors of the ceramide metabolic pathway for overcoming immunotherapy resistance in cancer
AU2023342055A1 (en) 2022-09-15 2025-03-13 Abbott Laboratories Biomarkers and methods for differentiating between mild and supermild traumatic brain injury
EP4593868A1 (en) 2022-09-26 2025-08-06 Institut Curie Myeloid cells expressing il-2 and uses thereof for quick anticancer therapy
US20260234258A1 (en) 2022-10-20 2026-08-13 Repertoire Immune Medicines, Inc. Cd8 t cell targeted il2
US20260151376A1 (en) 2022-10-20 2026-06-04 Institut National de la Santé et de la Recherche Médicale Combination therapy for the treatment of cancer
AU2023374571A1 (en) 2022-11-01 2025-04-03 Heidelberg Pharma Research Gmbh Anti-gucy2c antibody and uses thereof
JP2026504619A (ja) 2022-11-07 2026-02-06 ネオイミューンテック， インコーポレイテッド 非メチル化ｍｇｍｔプロモーターを含む腫瘍を治療する方法
WO2024112571A2 (en) 2022-11-21 2024-05-30 Iovance Biotherapeutics, Inc. Two-dimensional processes for the expansion of tumor infiltrating lymphocytes and therapies therefrom
JP2026501506A (ja) 2022-12-14 2026-01-16 アステラス・ファーマ・ヨーロッパ・ベスローデン・フェンノートシャップ Ｃｌｄｎ１８．２及びｃｄ３に結合する二重特異性結合剤並びに免疫チェックポイント阻害剤を含む併用療法
KR20250123912A (ko) 2022-12-21 2025-08-18 브리스톨-마이어스 스큅 컴퍼니 폐암에 대한 병용 요법
US20260217828A1 (en) 2023-01-31 2026-07-30 University Of Rochester Immune checkpoint blockade therapy for treating staphylococcus aureus infections
WO2024189048A1 (en) 2023-03-13 2024-09-19 Heidelberg Pharma Research Gmbh Subcutaneously administered antibody-drug conjugates for use in cancer treatment
WO2024196952A1 (en) 2023-03-20 2024-09-26 Bristol-Myers Squibb Company Tumor subtype assessment for cancer therapy
WO2024194402A1 (en) 2023-03-21 2024-09-26 Institut Curie Farnesyl transferase inhibitor for use in methods for the treatment of hrd cancer
WO2024194673A1 (en) 2023-03-21 2024-09-26 Institut Curie Methods for the treatment of dedifferentiated liposarcoma
EP4683630A1 (en) 2023-03-21 2026-01-28 Institut Curie Vps4b inhibitor for use in methods for the treatment of hrd cancer
KR20250164708A (ko) 2023-03-29 2025-11-25 다이이찌 산쿄 가부시키가이샤 항 cd25 항체 및 항 cd25 항체-약물 콘주게이트
JP2026517628A (ja) 2023-04-04 2026-06-02 アボット・ラボラトリーズ 対象が亜急性後天性脳損傷（ａｂｉ）を負った、負った可能性がある、又は負っていると推測されるかどうかを決定するためのバイオマーカーの使用
EP4695290A1 (en) 2023-04-13 2026-02-18 Institut Curie Methods for the treatment of t-cell acute lymphoblastic leukemia
WO2024213767A1 (en) 2023-04-14 2024-10-17 Institut National de la Santé et de la Recherche Médicale Engraftment of mesenchymal stromal cells engineered to stimulate immune infiltration in tumors
WO2024226971A1 (en) 2023-04-28 2024-10-31 Abbott Point Of Care Inc. Improved assays, cartridges, and kits for detection of biomarkers, including brain injury biomarkers
WO2024261302A1 (en) 2023-06-22 2024-12-26 Institut National de la Santé et de la Recherche Médicale Nlrp3 inhibitors, pak1/2 inhibitors and/or caspase 1 inhibitors for use in the treatment of rac2 monogenic disorders
WO2025003193A1 (en) 2023-06-26 2025-01-02 Institut National de la Santé et de la Recherche Médicale Sertraline and indatraline for disrupting intracellular cholesterol trafficking and subsequently inducing lysosomal damage and anti-tumor immunity
TW202515608A (zh) 2023-06-26 2025-04-16 以色列商坎布根有限公司 Ｉｌ—１８ｂｐ拮抗抗體及其於癌症治療之單一療法及組合療法的用途
WO2025006811A1 (en) 2023-06-27 2025-01-02 Lyell Immunopharma, Inc. Methods for culturing immune cells
WO2025012417A1 (en) 2023-07-13 2025-01-16 Institut National de la Santé et de la Recherche Médicale Anti-neurotensin long fragment and anti-neuromedin n long fragment antibodies and uses thereof
CN121712571A (zh) 2023-08-15 2026-03-20 百时美施贵宝公司 陶瓷羟基磷灰石色谱流通法
EP4770666A2 (en) 2023-09-01 2026-07-08 Children's Hospital Medical Center Identification of targets for immunotherapy in melanoma using splicing-derived neoantigens
WO2025052098A1 (en) 2023-09-08 2025-03-13 Mina Therapeutics Limited Tmem173 sarna compositions and methods of use
WO2025061993A1 (en) 2023-09-21 2025-03-27 Domain Therapeutics Anti-ccr8 monoclonal antibodies and their therapeutic use
CN122341642A (zh) 2023-09-21 2026-07-03 多曼治疗学公司 抗ccr8单克隆抗体及其治疗用途
WO2025068393A1 (en) 2023-09-27 2025-04-03 Institut Curie Methods for the treatment of fibrotic related diseases
AR134560A1 (es) 2023-12-08 2026-01-28 Astellas Pharma Inc Terapia de combinación que implica agentes de unión biespecíficos que se unen a cldn18.2 y cd3 y agentes que estabilizan o aumentan la expresión de cldn18.2
WO2025120867A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
WO2026033885A1 (en) 2024-08-08 2026-02-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2025120866A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
EP4574165A1 (en) 2023-12-21 2025-06-25 Egle Therapeutics Immunocytokine for cancer treatment
AU2024405515A1 (en) 2023-12-21 2026-07-02 Egle Therapeutics Immunocytokine for cancer treatment
CN122459678A (zh) 2023-12-29 2026-07-24 百时美施贵宝公司 KRAS抑制剂与Treg耗竭剂的组合疗法
WO2025151487A2 (en) 2024-01-08 2025-07-17 Regents Of The University Of Michigan Small-molecule inhibitors of adar1
AU2025213523A1 (en) 2024-01-26 2026-07-16 Centre National De La Recherche Scientifique Lipid degraders to trigger ferroptosis in cancer
TW202545568A (zh) 2024-01-29 2025-12-01 日商第一三共股份有限公司 抗her2抗體-藥物結合物與其他劑之組合
TW202545567A (zh) 2024-01-30 2025-12-01 美商思進公司 抗ｐｄ－ｌ１抗體和抗體－藥物共軛體及彼等在治療癌症的用途
WO2025166550A1 (zh) * 2024-02-06 2025-08-14 香港北恒生物科技有限公司 工程化细胞及其用途
TW202543581A (zh) 2024-02-12 2025-11-16 美商艾伊拉醫療公司 遞送組成物
US12521446B2 (en) 2024-02-27 2026-01-13 Bristol-Myers Squibb Company Anti-CEACAM5 antibody drug conjugates
US20250361320A1 (en) 2024-02-27 2025-11-27 Bristol-Myers Squibb Company Anti-ceacam5 antibodies and uses thereof
US20250282776A1 (en) 2024-03-05 2025-09-11 Bristol-Myers Squibb Company Bicyclic TLR7 Agonists and Uses Thereof
WO2025188694A1 (en) 2024-03-05 2025-09-12 Bristol-Myers Squibb Company Tricyclic tlr7 agonists and uses thereof
WO2025191529A1 (en) 2024-03-14 2025-09-18 Biohaven Therapeutics Ltd. Next generation riluzole prodrugs
WO2025202222A1 (en) 2024-03-25 2025-10-02 Institut National de la Santé et de la Recherche Médicale Therapeutic use of sting and tlrs agonists to induce p16 expression in immune cells
WO2025202213A1 (en) 2024-03-26 2025-10-02 Institut National de la Santé et de la Recherche Médicale Lipid nanoparticle loaded with antitumoral agent and functionnalized to target immosuppressive cells
WO2025202450A1 (en) 2024-03-28 2025-10-02 Institut Curie Myeloid cells modified by cytokine chimeric receptor and uses thereof
EP4624494A1 (en) 2024-03-29 2025-10-01 Institut Curie Her2 single domain antibody and uses thereof
WO2025210175A1 (en) 2024-04-04 2025-10-09 Centre National De La Recherche Scientifique Mutant csf-1r extracellular domain fusion molecules and therapeutic uses thereof
WO2025210252A1 (en) 2024-04-05 2025-10-09 Institut Curie Modulators of fam118b protein for use in therapy
WO2025217096A1 (en) 2024-04-08 2025-10-16 University Of Rochester Inhibitors of leucine-rich repeat kinase 2 (lrrk2) and medical uses thereof
WO2025217094A1 (en) 2024-04-08 2025-10-16 University Of Rochester Interleukin receptor-associated kinase (irak) protac degraders and medical use thereof
WO2025219595A1 (en) 2024-04-19 2025-10-23 Biper Therapeutics Method for combination treatments using alkynylbenzenesulphonamides for cancer therapy
WO2025232879A1 (en) 2024-05-10 2025-11-13 Cytocares (Shanghai) Inc. Anti-lilrb2 monospecific and bispecific antibody constructs and uses thereof
WO2025245489A1 (en) 2024-05-24 2025-11-27 Bristol-Myers Squibb Company Treatment of tumors in subjects having fgl-1 positive samples
WO2025248505A1 (en) 2024-05-31 2025-12-04 Wayne State University Methods for treating endometrial and ovarian hyperproliferative disorders
WO2026006604A1 (en) 2024-06-26 2026-01-02 Lyell Immunopharma, Inc. Feeder cell replacement
WO2026012976A1 (en) 2024-07-08 2026-01-15 Institut National de la Santé et de la Recherche Médicale Use of inhibitor of gasdermind for treatment of rac2 monogenic disorders
WO2026039642A1 (en) 2024-08-16 2026-02-19 Ardeagen Corporation Anti-mesothelin antibody conjugates and methods of use thereof
EP4707296A1 (en) 2024-09-05 2026-03-11 Egle Therapeutics Interleukin-2 variants with modified biological activity
EP4707295A1 (en) 2024-09-05 2026-03-11 Egle Therapeutics Interleukin-2 variants with modified biological activity
WO2026052851A2 (en) 2024-09-09 2026-03-12 Institut National de la Santé et de la Recherche Médicale Inhibitor of ciliogenesis for use in a method of preventing therapeutic resistance in cancer
WO2026072557A2 (en) 2024-09-24 2026-04-02 Genzyme Corporation Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof
WO2026096695A1 (en) 2024-10-31 2026-05-07 Bristol-Myers Squibb Company Anti-fucosyl-gm1 antibody drug conjugates
WO2026093526A1 (en) 2024-10-31 2026-05-07 Institut National de la Santé et de la Recherche Médicale Methods of predicting cancer in patients having premalignant lesions
WO2026093520A1 (en) 2024-10-31 2026-05-07 Institut Curie Short-csf1-associated extracellular vesicles and uses thereof
WO2026093435A1 (en) 2024-10-31 2026-05-07 Institut National de la Santé et de la Recherche Médicale Use of jak inhibitors for enhancing the potency of immunotherapy in the treament of cancer
WO2026106969A1 (en) 2024-11-15 2026-05-21 University Of Rochester Novel inhibitors of interleukin receptor- associated kinase
US20260144884A1 (en) 2024-11-22 2026-05-28 Bristol-Myers Squibb Company Anti-lrrc15 antibody drug conjugates
US20260144885A1 (en) 2024-11-22 2026-05-28 Bristol-Myers Squibb Company Anti-lrrc15 antibodies and uses thereof
WO2026112559A1 (en) 2024-11-25 2026-05-28 Genzyme Corporation Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof
WO2026112563A1 (en) 2024-11-25 2026-05-28 Abbott Laboratories Systems and methods for tbi adjudication
WO2026154125A2 (en) 2025-01-17 2026-07-23 Institut Curie A tumor-specific hla-bound neoantigenic peptide encoded by ewsr1::fli1-induced neogenes
WO2026162712A1 (en) 2025-01-31 2026-08-06 Institut National de la Santé et de la Recherche Médicale Methods for treating solid cancers combining low thermal-induced therapy and immunotherapy

Family Cites Families (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4681581A (en) 1983-12-05 1987-07-21 Coates Fredrica V Adjustable size diaper and folding method therefor
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
GB2183662B (en) 1985-04-01 1989-01-25 Celltech Ltd Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4954617A (en) 1986-07-07 1990-09-04 Trustees Of Dartmouth College Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
DE3708238A1 (de) 1987-03-16 1988-09-29 Motoren Werke Mannheim Ag Kraft-waerme-kopplungsanlage
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
JPH02500329A (ja) 1987-05-21 1990-02-08 クリエイテイブ・バイオマリキユールズ・インコーポレーテツド ターゲット化多機能蛋白質
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5648471A (en) 1987-12-03 1997-07-15 Centocor, Inc. One vial method for labeling antibodies with Technetium-99m
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
GB8912497D0 (en) 1989-05-31 1989-07-19 Cobbold Stephen P Monoclonal antibodies
CA2065299C (en) 1989-08-09 2001-07-24 Buck A. Rhodes Direct radiolabeling of antibodies and other proteins with technetium or rhenium
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2090473A1 (en) 1990-08-29 1992-03-01 Robert M. Kay Homologous recombinatin in mammalian cells
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US6300129B1 (en) * 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5194594A (en) 1990-09-07 1993-03-16 Techniclone, Inc. Modified antibodies
WO1992022670A1 (en) 1991-06-12 1992-12-23 Genpharm International, Inc. Early detection of transgenic embryos
AU2235992A (en) 1991-06-14 1993-01-12 Genpharm International, Inc. Transgenic immunodeficient non-human animals
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
US5770197A (en) 1991-06-27 1998-06-23 Bristol-Myers Squibb Company Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
DE69226871T3 (de) 1991-06-27 2009-09-24 Bristol-Myers Squibb Co. CTL4A-Rezeptor, ihn enthaltenden Fusionsproteine und deren Verwendung
EP0593592B1 (en) 1991-07-08 1998-03-25 The University Of Massachusetts At Amherst Thermotropic liquid crystal segmented block copolymer
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
JPH07503132A (ja) 1991-12-17 1995-04-06 ジェンファーム　インターナショナル，インコーポレイティド 異種抗体を産生することができるトランスジェニック非ヒト動物
US5777085A (en) 1991-12-20 1998-07-07 Protein Design Labs, Inc. Humanized antibodies reactive with GPIIB/IIIA
WO1993016043A1 (en) 1992-02-18 1993-08-19 Otsuka Kagaku Kabushiki Kaisha β-LACTAM COMPOUND AND CEPHEM COMPOUND, AND PRODUCTION THEREOF
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
GB9223377D0 (en) 1992-11-04 1992-12-23 Medarex Inc Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
US5773253A (en) 1993-01-22 1998-06-30 Bristol-Myers Squibb Company MYPPPY variants of CTL A4 and uses thereof
AU693436B2 (en) 1993-03-09 1998-07-02 Genzyme Corporation Isolation of components of interest from milk
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE69425890D1 (de) 1993-06-04 2000-10-19 Us Health Verfahren zur behandlung von kaposi-sarcoma mit antisense-oligonukleotide
JPH08506247A (ja) 1993-07-09 1996-07-09 アムジェン ボールダー インコーポレイテッド 組換えｃｔｌａ４ポリペプチドおよびその製造方法
EP0711345A1 (en) 1993-07-26 1996-05-15 Dana Farber Cancer Institute B7-2: ctl a4/cd 28 counter receptor
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
EP1025856A3 (en) 1994-03-08 2002-10-16 Dana-Farber Cancer Institute Methods for modulating T Cell unresponsiveness
US6719972B1 (en) 1994-06-03 2004-04-13 Repligen Corporation Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies
US5643763A (en) 1994-11-04 1997-07-01 Genpharm International, Inc. Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating
EP0804604A2 (en) 1995-01-20 1997-11-05 Cell Genesys, Inc. Method to improve screening efficiency in fused cells
US5703057A (en) 1995-04-07 1997-12-30 Board Of Regents The University Of Texas System Expression library immunization
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5618912A (en) * 1995-05-04 1997-04-08 Pennzoil Products Company Tire sealer and inflator compositions
US6410690B1 (en) 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5855887A (en) 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
EP0773288A3 (en) 1995-08-29 1997-07-09 Kirin Brewery Chimera animal and its method of manufacture
US6025130A (en) 1996-04-04 2000-02-15 Mercator Genetics, Inc. Hereditary hemochromatosis gene
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
DE69841452D1 (de) 1997-02-28 2010-03-04 Kyowa Hakko Kirin Co Ltd Humanes Chromosomfragment und ein Vektor, der dies enthält
EP0970128A1 (en) 1997-03-21 2000-01-12 Brigham And Women's Hospital Immunotherapeutic ctla-4 binding peptides
WO1998046996A2 (en) 1997-04-11 1998-10-22 The John P. Robarts Research Institute Lck serine phosphorylation assay for t-cell activation and activation-induced cell death
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
CA2205680A1 (en) 1997-05-16 1998-11-16 The University Of Western Ontario Clip immunomodulatory peptide
US6509057B2 (en) 1998-04-01 2003-01-21 Sumitomo Osaka Cement, Co., Ltd. Antibacterial, antifungal or antialgal article and process for producing same
CA2241621A1 (en) 1998-06-26 1999-12-26 National Silicates Ltd. A lubricating method for silicate drilling fluids
TWI255853B (en) 1998-08-21 2006-06-01 Kirin Brewery Method for modifying chromosomes
ATE397457T1 (de) 1998-12-03 2008-06-15 Univ California Stimulierung von t-zellen gegen selbstantigene unter verwendung von ctla-4 inhibierenden wirkstoffen
ES2706547T3 (es) * 1998-12-23 2019-03-29 Pfizer Anticuerpos monoclonales humanos para CTLA-4
US6682736B1 (en) * 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
IT1395574B1 (it) 2009-09-14 2012-10-16 Guala Dispensing Spa Dispositivo di erogazione
US9169311B2 (en) 2013-03-15 2015-10-27 Applied Food Biotechnology, Inc. Feline bitter taste receptors and methods
KR102264548B1 (ko) 2014-11-21 2021-06-16 삼성전자주식회사 반도체 패키지 및 그 제조 방법

Also Published As

Publication number Publication date
CA2381770C (en) 2007-08-07
EP1212422B1 (en) 2007-02-21
WO2001014424A3 (en) 2001-09-20
CN102766210A (zh) 2012-11-07
JP5599158B2 (ja) 2014-10-01
JP2004512005A (ja) 2004-04-22
IL189629A0 (en) 2008-06-05
CN1371416B (zh) 2012-10-10
IL148079A0 (en) 2002-09-12
JP2006151993A (ja) 2006-06-15
WO2001014424A2 (en) 2001-03-01
DK1212422T3 (da) 2007-07-02
KR20060100950A (ko) 2006-09-21
KR20020047132A (ko) 2002-06-21
AU2009202447A1 (en) 2009-07-09
CY1107628T1 (el) 2013-04-18
ATE354655T1 (de) 2007-03-15
CN1371416A (zh) 2002-09-25
JP4093757B2 (ja) 2008-06-04
PT1212422E (pt) 2007-04-30
AU2006201520B9 (en) 2009-08-27
CN102766210B (zh) 2015-07-08
CA2381770A1 (en) 2001-03-01
EP1792991A1 (en) 2007-06-06
CA2589418A1 (en) 2001-03-01
BE2012C001I2 (enExample) 2019-10-16
KR100942863B1 (ko) 2010-02-17
DE60033530D1 (de) 2007-04-05
CY2012002I2 (el) 2020-05-29
EP1212422A2 (en) 2002-06-12
AU2006201520A1 (en) 2006-05-11
JP2009213478A (ja) 2009-09-24
AU784012B2 (en) 2006-01-12
FR12C0004I2 (fr) 2013-01-11
DE122012000001I1 (de) 2012-03-15
DE60033530T2 (de) 2007-10-31
LU91928I2 (fr) 2012-03-09
US6984720B1 (en) 2006-01-10
AU2009202447B2 (en) 2011-11-24
IL148079A (en) 2008-04-13
EP3214175A1 (en) 2017-09-06
HK1048831A1 (en) 2003-04-17
ZA200201190B (en) 2003-05-28
KR100996759B1 (ko) 2010-11-25
CY2012002I1 (el) 2016-12-14
EP2829609A1 (en) 2015-01-28
ES2282133T3 (es) 2007-10-16
AU7073200A (en) 2001-03-19
AU2006201520B2 (en) 2009-03-19
NZ517202A (en) 2004-05-28
FR12C0004I1 (enExample) 2012-02-24
JP2012100674A (ja) 2012-05-31
KR20090036598A (ko) 2009-04-14

Similar Documents

Publication Publication Date Title
FR12C0004I1 (enExample)
NL300433I1 (en) Methods and compositions for the treatment of glomerulonephritis
PT1132403E (pt) Peptidos inibidores de tgf g beta1
MXPA02011656A (es) Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
MY136095A (en) Use of human anti-ctla-4 antibodies for treatment of cancer
IL130931A0 (en) Small molecules useful in the treatment of inflammatory disease
MX9800625A (es) Marcfortinas y paraherquamidas antiparasitarias.
MY155218A (en) Small molecules useful in the treatment of inflammatory disease
IL129592A0 (en) 5-HT1f agonists
IL125124A0 (en) Dimeric forms of the protein fapalpha and uses thereof
MX9704030A (es) 1,1-dioxidos de 2-heterocicliloxi y tiometil-1,2,5-tiadiazolidin-3-ona y composiciones y metodo de uso de los mismos.
ATE438630T1 (de) 5-sulfanyl-4h-1,2,4-triazolderivate und deren verwendung zur behandlung von somatostatine vermittelten krankheiten
IT1293690B1 (it) Stent per angioplastica, particolarmente per il trattamento di lesioni aorto-ostiali ed ostiali.
IL142900A0 (en) Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
ZA965565B (en) Novel peptides derived from human heat shock protein 60 for treatment of diabetes, compositions, methods and kits.
ZA200003768B (en) Methods and compositions for treating diseases and conditions of the eye.
FI974640A7 (fi) Migreenin hoitoon tarkoitetut 1,6-disubstituoidut isokromaanit
IL135634A0 (en) 5-htif agonists
PT929299E (pt) 1,2,3,4-tetra-hidro-2-dibenzofuranaminas e 2-aminociclo-hepta ¬b| benzofuranos substituidos
AU1278600A (en) Novel therapeutic application of nicergoline
IL143279A0 (en) Novel therapeutic application of low molecular weight heparin
AU7478098A (en) Methods of treatment using nbs-1, antibodies and proteins thereto, and uses of the antibodies
DK1133297T3 (da) Ny terapeutisk anvendelse af 1,6-dimethyl-8beta-hydroxymethyl-10alpha-methoxyergolin
ZA989313B (en) Novel compounds for treating diseases associated with the biological effect of endothelin.
SI0874843T1 (en) Substituted 4-(1h-benzimidazol-2-yl) 1,4)diazepanes useful for the treatment of allergic diseases

Legal Events

Date Code Title Description
FG Grant or registration
GD Licence granted
GB Transfer or rights